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Anticholinesterase organophosphate (OP) compounds were developed as
insecticides and are also used as nerve agents in chemical warfare. Treatment against
acute OP toxicity includes oximes which reactivate phosphorylated acetylcholinesterase
(AChE) restoring enzymatic activity. The oxime currently approved for use in the U.S.,
pralidoxime (2-PAM), has limited efficacy penetrating the blood-brain barrier. Our
laboratory has developed novel substituted phenoxyalkyl pyridinium oximes (US Patent
9,227,937) designed to more effectively penetrate the central nervous system. This
research investigated any differences in oxime reactivation among four age/sex groups
and also survivability in adult female Sprague Dawley rats challenged with a lethal dose
of OP. Initially in in vitro experiments, paraoxon (PXN) and a nerve agent (sarin)
surrogate, 4-nitrophenyl isopropyl methylphosphonate (NIMP), were incubated with
pooled rat brain homogenate from four sex/age groups: adult male or female, and 12-day
old male or female rats. Reactivation was performed utilizing 2-PAM or one of three
novel oximes (15, 20, or 55), alone or in combination, and AChE activity was measured
in a spectrophotometric assay. Overall, the oximes were more effective reactivating

inhibition from PXN than from NIMP. Out of all the oximes tested, 2-PAM showed the
greatest reactivation percentages. Of the novel oximes, 15 and 20 displayed the highest
reactivation against PXN and NIMP, respectively. No statistical difference was detected
in reactivation for any oxime among the age/sex groups. For the in vivo study, female
adult Sprague-Dawley rats were treated with LD99 dosages of NIMP or PXN. After
development of seizure-like behavior, atropine and one of four oximes, 2-PAM, novel
oxime 15, 20, or 55 or Multisol vehicle was administered. Animals were closely
monitored for signs of cholinergic toxicity and 24-hour survivability. Against PXN,
novel oximes 15 and 55 demonstrated an improved odds ratio of 6.5 and 3.1,
respectively, over 2-PAM. The most effective oxime against NIMP was novel oxime 20
demonstrating an odds ratio of 3.2 over treatment with 2-PAM. These data indicate that
the novel pyridinium oximes are equally efficacious reactivators in adult and juvenile rats
of both sexes and enhance survivability against lethal-level OP toxicity as compared to 2PAM in adult female rats.
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CHAPTER I
INTRODUCTION
Significance of Organophosphates
Organophosphate (OP) chemicals encompass a large group of compounds with
diverse properties and molecular structures. Although OPs are most commonly
associated with insecticides, they can also be found in oils, lubricants, plasticizers and
flame retardants (Winder and Balouet, 2002). Common to all OPs is the pentavalent
phosphorus atom which can form three, single covalent bonds to a variety of constituents,
and a fourth, double bond typically linked to either a sulfur or oxygen atom. It is this
phosphorus atom, often forming a phosphate or phosphorothionate group within the
center of the molecule, which gives these compounds their name (Mileson et al., 1998).
Infamously, nerve agents are OP compounds specifically designed for chemical
warfare. Nerve agents were initially developed in Germany derived from insecticides in
the 1930s; however, because they can be easily absorbed through the skin and/or inhaled,
when combined with their potent anticholinesterase characteristics, it made them too
dangerous for agricultural use. Almost immediately after their discovery, these same
characteristics made them ideal for weaponization by the Nazi party. The first group of
nerve agents developed were the G-series agents. Designated “G” representing the
Germans who developed them, and a second letter identifies the specific compound: GA
(tabun), GB (sarin), GD (soman), and GF (cyclosarin). Additional series of nerve agents
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have been developed since; the V-series of agents include the compounds VE, VG, VM
and VX (Chambers and Carr, 2002; Rotenberg and Newmark, 2003; Johnson et al.,
2015). Although never used during World War II, history is replete with examples of OP
utilization as weapons in military operations or terroristic acts. The government of Iraq
used nerve agents in a conflict against the Iranian military from 1981 to 1988. During the
same time period, Iraqi forces dropped bombs containing sarin and tabun on the Kurdish
village of Halabja killing thousands of civilians (BBC, 2013; Johnson et al., 2015). A
cult in Japan, Aum Shinrikyo, deployed sarin gas in 2 separate attacks in 1994 and 1995
(Rotenberg and Newmark, 2003; Johnson et al., 2015). More recently, the Syrian regime
was implicated in the usage of sarin nerve agent in 2013 and 2017 during its civil war
affecting civilian populations in rebel-held territory (Associated Press, 2017).
Since their discovery, the threat of chemical attack with weaponized OP
compounds has not diminished with the passage of time; however, their potent
neurotoxicity alone is not the only characteristic which drives their utilization. Chemical
precursors used in the creation of nerve agents are easily procured, and the procedure for
their synthesis can be accomplished through relatively simple means. Often colorless and
odorless, small quantities of nerve agent are easily concealed and can have devastating
effects if deployed properly (Johnson et al., 2015; Musser, 2001; Rotenberg and
Newmark, 2003). These are characteristics which may appeal to a terrorist organization
with limited resources who are looking to make a large impact without regard for
international retaliation. Even if access to the necessary precursors for production of a
nerve agent such as sarin are unavailable or restricted, other organophosphorus
2

insecticides could be repurposed to such ends (Bajgar et al., 2015). While the usage of
organophosphorus insecticides in the United States has been decreasing since the passage
of the Food Quality Protection Act in 1996, they still account for approximately 33% of
all insecticides used (Atwood and Paisley-Jones, 2017). Worldwide usage is prevalent,
especially in underdeveloped nations which rely on the inexpensive insecticides in
agriculture (Soltaninejad and Shadnia, 2014). These organophosphorus insecticides,
originally intended for agricultural use, represent sources from which terrorist groups
could obtain compounds with relatively high toxicity for malevolent purposes (Bajgar et
al., 2015). They also represent a source of occupational hazard from accidental exposure
and a disturbing trend is occurring in agricultural, socioeconomically depressed areas
across Africa and South Asia where OP insecticides are utilized by individuals who wish
to commit suicide (Adinew et al. 2017; Eddleston et al., 2009; Güllü et al., 2013; Pawar
et al., 2006; Singh et al., 1995).
Mechanism of Action and Toxic Effects
Many OP compounds are not inherently potent anticholinesterase agents, but
rather, the parent molecule must be bioactivated into their more active ‘oxon’ species in
order to exert their toxic effects (Neal, 1980). It is widely known, that the cytochrome
P450 monooxygenase (P450) system is responsible for this bioactivation (Chambers et
al., 2010). For instance, in 1951, the OP insecticide parathion was known to be a potent
cholinesterase inhibitor in vivo, but it had very minimal effects when in vitro inhibition
tests were attempted. It was later discovered that in the presence of liver tissue,
anticholinesterase activity was demonstrated. The postulation was made that an enzyme
3

in the liver tissue, which we now know is P450 and to a lesser extent, flavin-containing
monooxygenase, transform parathion into a capable inhibitor of cholinesterase. This was
later confirmed in 1952 when paraoxon was isolated from liver tissue in an in vivo test
and matched with the results of the previous in vitro study (Gage, 1952).
Phosphorothionate insecticides which have a pentavalent phosphorus atom with
one coordinate covalent bond attached to a sulfur atom must be bioactivated by P450.
The P450-mediated desulfuration reaction facilitates an attack of the phosphorus atom by
an oxygen atom, ultimately releasing sulfur (Neal, 1980). It is this substitution which
forms the more potent oxon species which is then reactive towards non-target,
endogenous serine esterases as well as acetylcholinesterase (AChE). Some
phosphorothionate insecticides requiring bioactivation include parathion, malathion,
chlorpyrifos, and phorate, while those OP compounds which do not require bioactivation
from their parent molecule include dichlorvos and the nerve agents soman, sarin, tabun,
and VX (Chambers et al., 2010).
As mentioned previously, OP compounds are best known for their acute
toxicological effects as cholinesterase enzyme inhibitors. The mechanism of action of
OPs lies in their ability to phosphorylate the serine hydroxyl moiety within the active site
of esterases. Acute toxicity of an OP compound is often characterized by measuring the
dosage at which 50% of the experimental subjects have a lethal response or outcome,
otherwise known as LD50. The LD50 of an OP compound depends upon the
cholinesterase inhibiting potency, rate of aging, and lipophilicity of the OP molecule.
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Higher lipophilicity means that an OP can penetrate cellular barriers easier and achieve a
greater volume of distribution (Misik et al., 2015).
In a normal functioning nervous system, the action and degradation of the
neurotransmitter acetylcholine (ACh) is extremely quick, occurring within a few
milliseconds. Excitation of a neuron causes vesicles storing ACh to fuse with the presynaptic membrane. Upon releasing into the synaptic cleft, the hydrophilic ACh quickly
diffuses the short 20 nm span to the post-synaptic membrane where binding occurs to its
corresponding receptor. Almost instantly after binding, ACh is hydrolyzed by AChE into
acetic acid and choline, thereby terminating the excitatory stimulus. Unlike other
neurotransmitters which have a variety of mechanisms to mitigate their signal, ACh
depends almost entirely upon the quick action of AChE which underscores why inhibitors
of this enzyme are so toxicologically potent. Disruption of AChE by an inhibitor such as
an OP or carbamate allows the neurotransmitter to accumulate and excessively prolong
the stimulatory signal with no immediate remedy for termination (Kobayashi and Suzuki,
2010).
By inhibiting AChE, the target enzyme for OPs, ACh can remain in cholinergic
synapses generating persistent excitatory stimuli to an organism’s nervous system. A
range of sympathetic and parasympathetic nervous system symptoms in mammals can
occur including salivation, lacrimation, urination, and defecation, in a syndrome termed
‘SLUD’, as well as muscle spasms and tremors (Chambers et al., 2001; Chambers and
Carr, 2002). Overstimulation of the central nervous system due to increased levels of
ACh within the hippocampus of the brain activate muscarinic and nicotinic receptors
5

which stimulate the release of the excitatory neurotransmitter glutamate inducing
convulsions or seizure activity (Kozhemyakin et al., 2010; Todorovic et al., 2012).
Ultimately, the cause of death in cases of acute OP toxicity is respiratory failure due to
paralysis of muscles important for inspiration (Costa, 2008).
Oxime Therapy
There are an estimated three million cases of OP poisoning worldwide each year
with approximately 200,000 occurring in developing countries (Adinew et al., 2017).
Treatment for OP poisoning includes a regimen of different drugs. Sedatives such as a
benzodiazepine like diazepam are employed for treatment of seizures associated with
central nervous system poisoning. A muscarinic antagonist, such as atropine, can block
or dampen some of the peripheral nervous system symptoms (Kassa, 2002). Atropine is
considered a staple of OP poisoning treatment and given at high dosages, titrated by
monitoring secretions and pupil size (Karakus et al., 2014; Singh et al., 1995). Finally,
an oxime, such as pralidoxime (2-PAM), can be utilized to reactivate AChE
phosphorylated by an OP compound; however, while treatment with atropine is well
accepted, oxime therapy has been somewhat more controversial (Eddleston et al., 2006;
Thiermann et al., 2011).
Since the discovery of oximes in 1955, only a handful have seen clinical use: 2PAM, trimedoxime, obidoxime, and HI-6 (Childs et al., 1955). These early oximes
represent the entire current standard of oxime therapy out of thousands created in the
laboratory since the 1950s and 1960s (Worek et al., 2016). Oximes all contain
similarities within their molecular structure which are responsible for their mechanism of
6

action. A quaternary nitrogen pyridinium ring serves to position the molecule within the
active site of AChE allowing the oxime moiety (RCH = NOH) to conduct a nucleophilic
attack on the serine hydroxyl group phosphorylated by the OP thereby transferring the
phosphoryl group to the oxime. This transfer restores the serine hydroxyl group within
the AChE active site, reactivating its enzymatic potential.
When an OP compound phosphorylates a serine esterase, such as AChE or
butyrylcholinesterase, the reaction is often referred to as irreversible inhibition of the
enzyme. Esterases however, can undergo spontaneous reactivation through hydrolytic
cleavage of the phosphoryl moiety returning the active site of the enzyme to its
physiologic normal state although this reaction is very slow. Another reaction can also
occur, instead of hydrolysis, a dealkylation can occur leaving a monoalkoxy phosphate
bound to the active site in a process termed “aging”. When an enzyme undergoes aging,
the inhibition is permanent and resists reactivation even in the presence of an oxime
antidote (Kobayashi and Suzuki, 2010; Kassa, 2002).
This relationship between reactivation and aging varies among OP compounds
and which serine esterase they are phosphorylating. For example, dimethyl OPs age
more rapidly than diethyl OPs with aging half-lives of 3.7 hours and 31 hours,
respectively (Milatovic and Jokanovic, 2009). The nerve agent GD, or soman, rapidly
ages with 50% of the inhibited enzyme aging within 1.3 minutes as measured in red
blood cell cholinesterase (Watson et al., 2009). This has important therapeutic
implications with regard to the timing for administration of an oxime antidote after an
exposure event as the structure of the OP compound is an important determinant for
7

oxime effectiveness and the patient’s prognosis. It was demonstrated that reactivation of
dimethylphosphorylated AChE with 2-PAM, as measured in RBCs, is less effective than
it would be otherwise in a patient exposed to a diethyl OP compound (Hansen and
Wilson, 1999). Clinical studies which do not control for the exposure time or OP
compound to which a patient is exposed may be skewing results of oxime effectiveness
as 2-PAM would not be expected to work for those patients exposed to a dimethyl OP
compound and receiving oxime therapy after aging has already occurred (Eddleston et
al., 2006).
The rate of aging by which phosphorylated AChE becomes resistant to
nucleophilic attack by an oxime is just one of a number of factors influencing the
effectiveness of oximes. Reactivation depends upon subtle differences in oxime
molecular structure which influence their affinity for an OP-inhibited enzyme based on
factors such as spatial orientation and steric hindrance within the active site. Additional
factors affecting reactivation include inhibitory affinity of the oxime itself towards
AChE, pharmacokinetics of oxime therapy, as well as inhibitory potency and
concentration of the OP (Kassa, 2002; Milatovic and Jokanovic, 2009; Worek et al.,
2016). These intricacies in the interaction between oxime and OP-phosphorylated
enzyme in a real-world clinical environment with varying degrees of exposure, different
OPs, timing of the initiation of treatment and available clinical resources have led to
confounding studies (Eddleston et al., 2006).
The necessity of therapy with oximes in acute OP poisoning has been questioned
in lieu of monotherapy with atropine in combination with supportive treatment such as
8

mechanical ventilation and intravenous fluids (Singh et al., 1995). A meta-analytic study
analyzing over 3,000 articles reviewing the clinical treatment of OP poisoning indicated
that usage of oximes had a negligible effect on the outcome of the patient. Two different
oximes, obidoxime or 2-PAM, were administered in these studies and were actually
associated with possible harm as those patients demonstrated an increased need for
intensive care when oxime therapy was given (Peter et al., 2006). Pawar et al., compared
a higher dose regimen 2-PAM treatment (1g/hour) to their standard lower dose (1g/4
hour) after a 2g loading dose. This study demonstrated that the higher 2-PAM dose
group required less atropine and decreased the need and duration of ventilation in cases
of moderate to severe OP insecticides poisoning (Pawar et al., 2006). Even partial
reactivation of AChE by an oxime can significantly reduce the amount of atropine needed
(Thiermann et al., 2011). Conversely, Eddleston et al. (2009) performed a study that
randomized treatment of 235 patients with OP self-poisoning administering either
placebo or 2-PAM using the World Health Organization’s (WHO) recommended regimen
(2 g loading dose over 20 minutes followed by 7 days of 0.5 g/hour constant infusion or
until atropine was not needed for 12-24 hours or death occurred). The main conclusion
of this trial was that there was no apparent benefit with the administration of 2-PAM
versus placebo. Furthermore, there was a 69% increase in mortality associated with 2PAM treatment. This study contrasts with Pawar et al. (2006) which showed high dose
2-PAM dosing beneficial to a patient’s outcome. Key differences existing between these
two studies include shorter term oxime administration and a higher level of intensive care
available used in the Pawar et al. (2006) trial. It is possible that the WHO’s
9

recommended oxime treatment guidelines include dosages that are too high or too long in
duration. RBC cholinesterase activity in survivors was 25% of normal indicating that
high amounts of AChE reactivation, and high doses of oxime by extension, may not be
needed to improve survivability (Eddleston et al., 2009).
High dose oxime therapy may cause increased mortality, while if used early after
OP exposure low dose oxime therapy may be beneficial (Peter et al., 2000). One
retrospective study of 179 medical records indicated that early treatment with 2-PAM
was associated with lower mortality in OP-poisoned patients which increased as time to
administration of oxime therapy increased (Güllü et al., 2013). Droste et al. (2016)
utilized physiologically based pharmacokinetic (PBPK) modeling to estimate treatment
of inhalational sarin exposure with atropine and 2-PAM. The model indicated that at a
high, incapacitating dose of sarin, oxime therapy is a beneficial, life-saving treatment
while oxime therapy in a victim displaying mild symptoms is not effective. In those
cases of mild to moderate exposure, supportive treatment with a benzodiazepine and
intravenous fluids as determined by a physician was recommended (Droste et al., 2016).
As mentioned before, multiple factors are responsible for apparent effectiveness of oxime
treatment which make evaluation of their usage in clinical therapy problematic. These
inconsistencies in the evaluation of oxime therapy can be attributed, in many cases, to
limitations of the experimental design within the studies themselves; however, there are
limitations associated with the clinically approved oxime in the U.S., 2-PAM (Eddleston
et al., 2006).
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Currently, there does not exist a single, broad-spectrum oxime which can be
considered effective against both nerve agents and OP insecticides. For example, 2-PAM
is an ineffective reactivator of AChE when inhibited by the nerve agent tabun,
presumably because of the nerve agent’s resistance to nucleophilic attack once bound
within the active site, but is considered an effective reactivator for OP insecticide
poisoning. Additionally, 2-PAM has difficulty penetrating the blood brain barrier due to
its charged structure (Cabal et al., 2004; Kassa, 2002). It is estimated that approximately
10% of the 2-PAM dose given penetrates the blood brain barrier in a concentrationdependent manner; however, researchers are unsure if this concentration is sufficient for
reactivation of OP-inhibited brain cholinesterase (Sakurada et al., 2003). The position of
the oxime group within the pyridinium ring can be an important indicator for efficiency
in crossing the blood-brain barrier. The oxime group exists in the ortho configuration or
position two on the pyridinium ring within 2-PAM. Using a modified high-performance
liquid chromatography method to simulate blood-brain penetration, researchers
determined that the most efficient configuration of a monoquaternary oxime for passage
into the brain is the para configuration with the oxime group attached to position four on
the pyridinium ring which linearizes the molecule minimizing the polar surface area
(Karasova et al., 2010).
Our laboratory has developed and patented a number of novel oximes which are
designed to cross the blood-brain barrier to attenuate OP-associated inhibition within the
central nervous system (Chambers et al., 2013). It has been demonstrated that 24-hour
survivability with a lethal dose of an OP compound is increased in adult male rats when
11

treated with these novel oximes versus 2-PAM (Chambers et al., 2016). These new
antidotes offer promising improvement over the current standard of oxime therapy;
however, more information is needed to validate their efficacy in both sexes and in
juveniles for continued development towards usage as clinical drugs.
Age and Sex-related Differences in Toxicity
Significant differences in xenobiotic metabolism have been reported between
species, sex, and age which may impact the way a novel oxime is administered in cases
of acute toxicity. For example, female rats have been found to be more sensitive to
pesticides than their male counterparts, while juvenile rats display more varying
sensitivity compared to adults. Weanling rats can be less sensitive, displaying higher
LD50 concentrations to certain chemicals, while adults have higher toxicity towards the
same compound and vice versa (Gaines and Linder, 1986). The mechanisms for these
differences are not entirely explained by age/sex-related differences in xenobiotic
metabolism, but can also depend on a variety of pharmacokinetic factors such as route of
exposure, membrane permeability, distribution and rate of excretion (Kassa, 2002). In
fact, more recent studies have demonstrated sex-hormone related differences in OP
lethality which must be considered for future studies in this field (Pittel et al., 2018;
Smith et al., 2015).
Often, for the sake of simplicity and to minimize variation in experimental design,
many studies have utilized adult male animal models. Unfortunately, the imprecise
nature in which nerve agents spread after employed as terrorist or area denial weapons
lead to the indiscriminate exposure of all in the affected contamination zone including
12

women and children (Johnson et al., 2015; Watson et al., 2009). Additionally, initial
animal studies which are disproportionately focused on males may lead to confounding
data and underestimate the influence of age and sex factors on health outcomes. The
National Institutes of Health (NIH) is now expecting that all research consider sex an
important biological variable in vertebrate and human studies. Sex should be factored in
to experimental design unless a strong scientific justification indicates otherwise (NIH,
2015).
Typically, adult female rats have been considered to be more sensitive to the
lethal effects of a nerve agent such as sarin (24 hour LD50 = 67 μg/kg i.m.) than their
male counterparts (24 hour LD50 = 88 μg/kg i.m.); however, this is not always the case
(Pittel et al., 2018). Significantly higher 24 hour sarin LD50 (125 μg/kg s.c.) was
observed in female rats while in proestrus phase of the estrus cycle versus female rats in
estrus phase or those with ovaries surgically removed. Although not statistically
significant, the LD50 of female rats in proestrus was higher than male rats (24 hour LD50 =
116 μg/kg s.c.) in the same experiment (Smith et al., 2015). In order to test new
therapeutics using female animal models, it is incumbent on the researcher to know at
what point in the estrus cycle the animal is in because increased levels of sex hormone
such as estrogen may affect the lethality of a given dose of OP compound and thereby
skew results for testing treatment effectiveness (Wright et al., 2016b). Furthermore, age
and sex-related differences can be seen between different nerve agents and there is poor
correlation between LD50 and cholinesterase inhibition suggesting that inactivation of
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AChE cannot be the sole mechanism to explain the lethal effects of OP intoxication
(Fawcett et al., 2009).
One of the ways hypothesized to account for these observations is that estrogen is
thought to have a protective effect on astrocytes which help maintain the permeability
characteristics of the blood-brain barrier (Pittel et al., 2018). Expression of inflammatory
cytokines such as IL-6, TNF, and IL-1β in response to OP exposure within the brain
increased in male astrocytes, but not in female astrocytes suggesting that female
astrocytes are better protected from production of reactive oxygen species associated with
inflammatory responses (Astiz et al., 2014). Additionally, increased concentrations of
MCP-1, a monocyte chemoattractant cytokine, found in the brains of female rats indicate
that this higher concentration recruits monocytes from the peripheral circulation in order
to better maintain the blood-brain barrier in females after sarin exposure as opposed to
males. Overall, females demonstrated better protection against brain damage induced by
sarin exposure but exhibited greater overall sensitivity (lower LD50) than their male
counterparts when controlling for the estrus cycle (Pittel et al., 2018). Treatment of male
rats with estrogenic compounds may induce P450 enzymes, the effect of which has been
demonstrated to increase the parathion LD50 by 150% (Robinson et al., 1978). In another
study, pretreatment with the estrogenic compound diethylstilbestrol enhanced the
reactivating capability of the oxime HI-6 in castrated male rats after exposure to nerve
agents (Lundy et al., 1989).
Age-related factors can have similar implications for animal studies.
Carboxylesterases are important scavenger enzymes which stoichiometrically eliminate
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OP compounds by acting as targets for phosphorylation. Paraoxonases are enzymes
which reside on high density lipoproteins that are involved in the prevention of
atherosclerosis via hydrolysis of cholesterol esters but also have demonstrated the ability
to detoxify OP compounds through the same mechanism (Harel et al., 2004). The
activity of protective enzymes in rats has been shown to dramatically increase with
maturation after puberty (Atterberry et al., 1997). Age-related differences exist for Gseries nerve agents, but not for V-series agents as measured by LD50. The V-series
agents do not react as well with carboxylesterases as do G-series which may account for
this observation (Wright et al., 2016b). Additionally, the surge in sex hormones
associated with puberty seem to confer a protective effect against the lethality of nerve
agents. Pubescent animals have been demonstrated to have higher sarin LD50 than
prepubescent and adult age groups (Fawcett et al., 2009; Wright et al., 2016a; Wright et
al., 2016b). When considering age as a factor in OP lethality, however, the maturational
expression of protective enzymes such as carboxylesterase or paraoxonase, may be more
toxicologically relevant than rising levels of sex hormones as demonstrated in a separate
study which found that younger rats were more susceptible to sarin than adult rats with
minimal sex-related differences (Wright et al., 2017). Conversely, younger rats have
been shown to be more resistant to neuronal damage from acute OP intoxication.
Researchers suggest this resistance is due to the under-developed nervous system in
juveniles, primarily the lower expression muscarinic receptors, which minimize the overstimulatory effects of excess ACh thereby preventing the development of brain damaging
seizures (Scholl et al., 2018).
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There exists a need for better countermeasures against OP toxicity as these
compounds represent a threat against human health as they continue to be used for
legitimate agricultural purposes as well as chemical weapons. The development of
improved antidotes, such as novel oximes, hinges on our ability to account for important
biological variables such as age and sex. Recent developments in this area of research
have pointed to clear age and sex-related differences in the responses to OP exposure.
While the science is still evolving with these findings, efforts to control for important
variables must be incorporated into experimental design if meaningful evaluation of new
treatments is to be successful. To further enhance understanding of OP intoxication with
the goal of developing more effective antidotes, new information regarding oxime
reactivation of AChE inhibited by OP compounds in mammals is needed.
Research Summary
This research is designed to elucidate the differences, if any, in the efficacy of our
novel oximes in females and, to a lesser extent, in juveniles which may be useful for
future research in their development as new antidotes. Performance of the novel oximes
will be compared against results obtained in male Sprague Dawley rats from previous
studies (Chambers et al., 2013; Chambers et al., 2016). Specifically, this research
investigates in vitro AChE oxime-mediated reactivation in brain tissue after OP inhibition
in male and female rats differing in age and determines in vivo novel oxime reactivating
efficiency and survival efficacy in the adult female Sprague Dawley rat dosed with either
the sarin surrogate, 4-nitrophenyl isopropyl methylphosphonate (NIMP) or paraoxon
(PXN), the active metabolite of the insecticide parathion. The in vitro work was
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performed under the hypothesis that appreciable differences do not exist between sex and
age when reactivating OP-inhibited AChE with oximes due to the conserved nature of the
enzyme. Additionally, the in vivo treatment of adult female rats with novel oximes
should have similar results as previous studies with adult males showing increased
survival rates and attenuated seizure-like signs when compared to 2-PAM.
The second chapter was dedicated to the in vitro work in which differences in
novel oxime reactivation were elucidated using pooled rat brain homogenate from 4
groups of Sprague Dawley rats: adult or postnatal day (PND) 70 males and females, and
juvenile or PND 12 males and females. Species differences are seen in the inhibitory
potential of OPs as well as reactivation by oximes which are believed to be due to small
variations in AChE structure (Worek et al., 2011). Despite these variations which may
exist in the non-catalytic portions of AChE, the catalytic site, responsible for enzymatic
action, is almost identical across many species (Moralev et al., 2001). Previous studies in
rats have shown that cholinergic activity rapidly increases postnatally from being
relatively low at 1 week of age to near adult activity levels after 4 weeks of maturation
(Coyle and Yamamura, 1976). Correspondingly, AChE activity has been demonstrated
to increase with age (Tang et al., 1999). Despite these age-related differences in activity,
the AChE enzyme is encoded by a single gene in vertebrate organisms and the active site
is highly conserved in mammals which share common coding exons and introns of the
same size and within the same sites on the gene (Massoulie et al., 1993). The target
enzyme should be reactivated by oximes in the same proportions regardless of age or sex
because of the consistency in functional structure.
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The OPs chosen for this work include one that is representative of a nerve agent,
NIMP, and PXN which is representative of a prototypical OP insecticide, both of which
give an assessment of the broad spectrum capability of our novel oximes. Several
surrogate compounds for nerve agents were developed for research purposes (Ohta et al.,
2006). NIMP phosphorylates AChE with the same moiety as the nerve agent sarin, but is
not volatile allowing for safer manipulation when conducting experimental protocol in
facilities not certified for nerve agent testing. The concentration in which 50% AChE
inhibition is achieved with NIMP is reported to be slightly higher than its nerve agent
counterpart as determined in brain tissue of adult male Sprague Dawley rats (Meek et al.,
2012). Three novel oximes designated oxime 15, 20, and 55 were selected from among
many other oximes as leading candidates for further drug development all of which were
first synthesized by Dr. Howard Chambers here at Mississippi State University (Meek et
al., 2012, Chambers et al., 2013). Past data from this laboratory have shown that
combination oxime therapy can be more effective than a single oxime alone. Combining
2-PAM with novel oximes has yielded higher 24 hour survival rates in OP lethal dosage
challenge studies (Chambers et al., 2016). Those combination studies were performed
with twice the molar equivalent of a single oxime concentration; therefore, this research
compares the higher concentration of combination oxime therapy versus an equimolar
concentration to help elucidate the efficacy of reactivation for differing levels of oximes
in combination.
In chapter 3, the three novel oximes were used to treat adult female rats dosed
with a LD99 concentration of either NIMP or PXN in a 24-hour survivability challenge
18

and compared to treatment with 2-PAM. Previous studies investigating the efficacies of
the novel oximes were performed on adult male rats. Against NIMP, novel oximes 15
and 20 demonstrated odds ratios of 2.3 and 1.8 compared to 2-PAM while novel oximes
15 and 55 increased PXN survivability 5.7 and 2.3 times greater than 2-PAM,
respectively (Chambers et al., 2016; unpublished data). Additionally, seizure-like
behavior was assessed using a modified Racine scale (Lüttjohann et al., 2009). A
decrease in the time until cessation of seizure-like behavior by monitoring signs of
cholinergic toxicity, as was demonstrated in male rats, supports the hypothesis that some
of these novel oximes are penetrating the blood-brain barrier (Chambers et al., 2016;
unpublished data).
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CHAPTER II
IN VITRO AGE AND SEX-RELATED DIFFERENCES IN OXIME REACTIVATION
Introduction
Organophosphate (OP) compounds, either insecticides or nerve agents, represent
a serious threat to human health when exposure occurs due to either accidental
occupational exposure, suicidal self-exposure, or by intentional terroristic acts (Adinew et
al. 2017, Bajgar et al., 2015, Johnson et al., 2015). The currently approved oxime used
in the United States for OP intoxication, pralidoxime (2-PAM), has significant limitations
with its ability to penetrate the blood-brain barrier, and broad spectrum capability against
a variety of OP compounds (Cabal et al., 2004; Kassa, 2002; Sakurada et al., 2003).
These reasons underscore the necessity of developing new and improved oximes as
antidotes to attenuate acute OP toxicity. Our laboratory has developed novel substituted
phenoxyalkyl pyridinium oximes (US Patent 9,227,937) designed to more effectively
penetrate the blood-brain barrier (Chambers et al., 2013). New information is needed to
further drug development and validate these new oximes with the ultimate goal of
creating more effective antidotes.
Initial studies with our novel oximes were performed using adult male rats as an
animal model (Chambers et al., 2013; Chambers et al., 2016a). If we are to further
develop these oximes into drugs, experiments must be performed which take into account
important biological variables such as age and sex. Differences do exist between
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acetylcholinesterase (AChE) of different species. Small differences in AChE structure
were detected between the fruit fly, torpedo, electric eel, mouse, and humans; however,
these differences were due to non-catalytic portions of the enzyme (Moralev et al., 2001).
These small differences were found to be relevant to an OP’s inhibitory potency with 10fold and 2-fold higher inhibitory rate constants found for human AChE inhibited by
paraoxon (PXN) as compared to guinea pig and rat AChE, respectively (Worek et al.,
2011). Additionally, expression of AChE in vertebrate animals rapidly increases as an
organism matures which may confound experimental design (Coyle and Yamamura,
1976; Tang et al., 1999).
Despite these differences, AChE is highly conserved and expressed by a single
gene in mammals (Massoulie et al., 1993). Reactivation of OP-inhibited AChE within
the same species should be similar between age and sex groups for each oxime. The
research presented in this chapter was designed to determine in vitro AChE oximemediated reactivation in brain tissue after OP inhibition in male and female rats of
different in ages.
Past data from this laboratory has shown that combination oxime therapy can be
more effective than a single oxime alone. Combining 2-PAM with novel oximes has
yielded higher 24-hour survival rates than single oximes in OP lethal dosage challenge
studies (Chambers et al., 2016a; Chambers et al., 2016b). Those combination studies
were performed with twice the molar equivalent of a single oxime concentration;
therefore, an in vitro study comparing this higher concentration of combination oxime
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therapy versus an equimolar concentration may be beneficial in elucidating the efficacy
of reactivation for differing levels of oximes in combination.
Materials and Methods
Chemicals
Several surrogate compounds for nerve agents were developed for research
purposes by Ohta et al., including the sarin surrogate, 4-nitrophenyl isopropyl
methylphosphonate (NIMP) used in this study (Ohta et al., 2006). Novel oximes 15, 20,
and 55, were first synthesized by Dr. Howard Chambers here at Mississippi State
University (Meek et al., 2012; Chambers et al., 2013). These oximes were later patented
(US patent 9,277,937) and are now synthesized by SRI International (Menlo Park, CA).
The NIMP used in this study was also synthesized at Mississippi State University. All
other reagents including 2-PAM and PXN, the active oxon of the insecticide parathion,
were purchased from the commercial vendors Sigma Chemical Co (St. Louis, MO) or
Thermo Fisher Scientific (Waltham, MA). Figure 1 displays the chemical structures
(created with MarvinSketch software, version 17.13.10) of the oximes and OP
compounds used in this study.
Animals
These in vitro assays used whole brain tissue from naïve Sprague Dawley rats
(Crl:CD(SD)BR). The rats were purchased from Envigo RMS, Inc. at postnatal day
(PND) 70 while PND 12 rats were obtained from breeding colonies maintained at
Mississippi State University from Envigo stock of the same strain. All animals were
housed in AAALAC accredited facilities within temperature-controlled environments
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with 12 hour dark-light cycle with Envigo 70-90 Sani Chips, laboratory grade bedding.
Rats had free access to Envigo Rodent Diet, 18% protein laboratory rat chow and tap
water. Procedures performed to harvest tissue for research purposes received prior
approval by the Mississippi State University Animal Care and Use Committee.
For these in vitro assays, the estrus cycle in adult (PND 70) female rats was not
controlled because the physiological barriers presumably bolstered by peaks in estrogen,
such as the blood-brain barrier, would be destroyed in the process of making homogenate
and the tissue is pooled from 5 animals in random stages of their cycle (Pittel et al., 2018;
Smith et al., 2015). Representing prepubescent, juvenile animals, the PND 12 age was
selected because at this stage the brain is still rapidly developing; however, cholinergic
activity is high enough to be easily assayed for comparison with the adults (Coyle and
Yamamura, 1976).
Tissue Collection and Preparation
Sprague Dawley rats were humanely euthanized utilizing CO2 for anesthesia
followed by decapitation. Harvested brain tissue was snap frozen in liquid nitrogen and
stored at -80°C until further preparation could be performed. Pooled homogenates of
whole rat brain from 5 animals were created for experimental replication utilizing a
motorized homogenizer and normalized via dilution in 50 mM Tris HCl buffer (pH 7.4 at
25°C) for approximately equivalent cholinesterase activity between the two age groups as
determined via a procedure described below. Three pools were created for both age
groups and for both sexes (12 pools consisting of 60 animals total). For PND 70 pooled
brain homogenate, the stock solution was 40 mg/mL wet weight equivalent with a
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cholinesterase assay final concentration (FC) of 1 mg/ml, while stock and final
concentrations of PND 12 animals were 65 mg/mL and 1.6 mg/ml wet weight equivalent,
respectively
Measurement of Cholinesterase Activity
Central to this research is the quantification of cholinesterase activity. This
cholinesterase assay is performed in conjunction with reactivation assays, which are
described later in this chapter, and performed to assay harvested tissues from the in vivo
studies outlined in the next chapter. To accomplish this measurement, a modified form of
the Ellman discontinuous spectrophotometric cholinesterase assay (Ellman et al., 1961)
was utilized.
Stock concentration of rat brain homogenate (40 mg/mL wet weight equivalent
for PND 70, 65 mg/mL wet weight equivalent for PND 12 in 50 mM Tris HCl buffer, pH
7.4 at 25°C) was aliquoted into 4 separate glass test tubes for each sample to be tested
diluted in 50 mM Tris HCl buffer for a 2 mL total assay volume (FC, 1 mg/mL and 1.6
mg/mL for PND 70 and PND 12, respectively). One tube was designated as a tissue
blank by the addition of 20 µL of eserine sulfate (FC, 0.01 mM) which inhibits all
cholinesterase activity in the tissue. This blank serves as measurement of background
interference caused by any non-AChE hydrolysis of the colorimetric substrate which is
subtracted from the final result. The other three tubes contain the sample in which tissue
cholinesterase is measured. These three tubes allow the assay to be performed in
triplicate for experimental replication. All tubes were vortexed and incubated at
physiologic relevant temperature, 37°C, in a shaking water bath to ensure the assay
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remains well mixed for 15 minutes. Next, 20 µL of acetylthiocholine (ATCh) was added
(FC, 1 mM) to all tubes which serves as a substrate for the tissue AChE within the rat
brain homogenate. This mixture was vortexed and incubated again for another 15 min at
37°C in a shaking water bath. Finally, 250 µL of a 4:1 mixture of 0.24 M 5,5’-dithio
bis(2-nitrobenzoic acid) (DTNB) and 5% sodium dodecyl sulfate (SDS) is added to each
tube. SDS is a detergent which disrupts proteins thereby terminating the reaction, while
DTNB reacts with thiocholine produced by the hydrolysis of ATCh substrate producing a
yellow color measurable by a Thermo Scientific Biomate 3 spectrophotometer at 412 nm.
This reaction produces absorbance values (A) directly proportional to the amount of
substrate hydrolyzed by AChE thereby allowing quantitation of cholinesterase activity
within the tissue.
The concentration of rat brain homogenate for PND 70 rats is consistent with
previous studies (Chambers et al., 2013) while the concentration for PND 12 rats was
determined experimentally by performing range finding assays with various dilutions of
rat brain homogenate until the cholinesterase activity was approximately similar to adults.
An additional age range was tested (PND 1); however, the cholinesterase activity was
determined to be too low for inclusion in this research under this experimental design
paradigm.
Reactivation of Acetylcholinesterase
In order to determine and compare the efficacy of the novel oximes, a reactivation
assay was performed utilizing AChE contained within rat brain homogenate consistent
with previous studies performed in this laboratory (Chambers et al., 2013). AChE was
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inhibited by one of two OP compounds, PXN or NIMP, with cholinesterase activity at
approximately 80% of maximum. This ensures that the rat brain homogenate is not
saturated with OP, which would falsely depress the apparent reactivation efficacy of the
oximes, while maintaining a large enough experimental range to adequately compare
reactivation capability between them. Each age/sex group was reactivated by each oxime
singularly or by combination of two oximes which are outlined in Table 1.
The reactivation assay procedure begins by placing 1 mL of stock concentration
rat brain homogenate into a 1.5 mL plastic centrifuge tube. This tissue homogenate is
incubated with 10 µL of ethanol (1% EtOH v/v) vehicle or OP (PXN or NIMP in EtOH).
At this point in the assay, the inhibition step, the concentration of PXN and NIMP was
100 nM and 56 nM, respectively, which produced about 80% cholinesterase inhibition in
the rat brain homogenate. The centrifuge tube receiving EtOH vehicle serves as the tissue
control which will retain maximal cholinesterase activity. Another tube will serve as an
inhibition control which will display the maximum inhibition produced by the OP while
multiple reactivation tubes are used for each oxime/oxime combination to be tested. All
tubes are vortexed and incubated in a shaking water bath at 37°C for 15 min. Next, in the
reactivation step, 10 μL of a 1:1 mixture of dimethyl sulfoxide (DMSO):EtOH vehicle
(1% v/v) is added to the tissue control tube and inhibition control tube while 10 μL of the
single oximes and 5 μL of each oxime for the oxime combinations are added to each
reactivation tube. All tubes are vortexed and incubated in a shaking water bath at 37°C
for 30 min. The tissue control tube ensures there is no significant enzyme inhibition from
the vehicles themselves while providing a measurement of maximal cholinesterase
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activity to which the reactivation tubes were compared. Finally, 250 μL from each
centrifuge tube is diluted in ice cold 50 mM Tris HCl buffer, pH 7.4 at 25°C (10 mL total
volume) to produce the final concentrations of rat brain homogenate, 1 mg/mL and 1.6
mg/mL for PND 70 and PND 12, respectively. For each sample, 2 mL is aliquoted into 4
separate glass test tubes and cholinesterase activity is assayed as described above.
Reactivation is calculated as a percentage of control determined by comparing
absorbance in the reactivation tubes against the tissue and inhibition control tubes.
Total cholinesterase inhibition percentage (Itotal) is calculated from absorbance values (A)
of the tissue control and inhibition control, less the background (blank):
𝐼𝑡𝑜𝑡𝑎𝑙 % =

(𝑇𝑖𝑠𝑠𝑢𝑒 𝐶𝑜𝑛𝑡𝑟𝑜𝑙−𝐵𝑙𝑎𝑛𝑘)−(𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 𝐶𝑜𝑛𝑡𝑟𝑜𝑙−𝐵𝑙𝑎𝑛𝑘)
(𝑇𝑖𝑠𝑠𝑢𝑒 𝐶𝑜𝑛𝑡𝑟𝑜𝑙−𝐵𝑙𝑎𝑛𝑘)

∗ 100

(1.1)

Next, the percentage of cholinesterase inhibition in each sample (Isample) is
calculated from absorbance values (A) of the tissue control and reactivation samples, less
the background interference (blank):
𝐼𝑠𝑎𝑚𝑝𝑙𝑒 % =

(𝑇𝑖𝑠𝑠𝑢𝑒 𝐶𝑜𝑛𝑡𝑟𝑜𝑙−𝐵𝑙𝑎𝑛𝑘)−(𝑅𝑒𝑎𝑐𝑡𝑖𝑣𝑎𝑡𝑖𝑜𝑛 𝑆𝑎𝑚𝑝𝑙𝑒−𝐵𝑙𝑎𝑛𝑘)
(𝑇𝑖𝑠𝑠𝑢𝑒 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝐴𝑣𝑔−𝐵𝑙𝑎𝑛𝑘)

∗ 100

(1.2)

Finally, the total reactivation percentage for each sample is calculated:
𝑅𝑒𝑎𝑐𝑡𝑖𝑣𝑎𝑡𝑖𝑜𝑛 % =

𝐼𝑡𝑜𝑡𝑎𝑙 −𝐼𝑠𝑎𝑚𝑝𝑙𝑒
𝐼𝑡𝑜𝑡𝑎𝑙

∗ 100

(1.3)

Oxime Control Studies
To ensure that the oximes or vehicles used in these experiments would not
significantly lower cholinesterase activity themselves, control studies were performed to
measure cholinesterase activity in rat brain homogenate with oximes in the absence of
any OP. The protocol for this experiment is very similar to the reactivation assay
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outlined above. Two separate pools of adult male rat tissue and female rat tissue were
utilized (4 pools total). Briefly, in 1.5 mL centrifuge tubes, 1 mL of rat brain homogenate
was added to the tissue control tube and each oxime control tube. There is no inhibition
control tube in this experiment. Next, 10 μL EtOH (1% v/v) was added to all centrifuge
tubes, vortexed, and incubated in a shaking water bath at 37°C for 15 minutes. From this
point forward, the procedure is identical to the above reactivation assay. Oximes were
tested at the same concentrations as outlined in Table 1. If an OP compound was present,
inhibited AChE would be reactivated by the oximes. Instead, all of the oxime control
samples were compared to the tissue control to ensure approximately equivalent
cholinesterase activity.
Oxime Effective Concentration
Reactivation and cholinesterase assays were performed using the procedures
above with various concentrations of oxime to determine the effective concentration at
which they achieve 25% reactivation (EC25). This experiment utilized brain homogenate
(40 mg/ml, 3 pools total) from naïve, adult male rats in which 80% of the cholinesterase
activity was inhibited by either PXN or NIMP (FC in 1 mL total volume, 100 nM and 56
nM, respectively). Experimental protocol was identical to the reactivation assay outlined
above. Reactivation efficacy for 2-PAM, novel oximes 15, 20, and 55 were tested at six
different concentrations in each pool of rat brain homogenate. Range-finding,
reactivation assays were performed to find the concentration at which maximal
reactivation activity was possible for each oxime. Step-wise, lower concentrations were
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then tested to yield a dose-response curve from which the EC25 could be calculated using
statistical software.
Statistical Methods
Each pool of rat brain homogenate served as an experimental unit for statistical
analysis in this research. Comparison of cholinesterase activity between the age/sex
groups was performed by a two-way ANOVA test to assess the difference in mean
absorbance utilizing the PROC GLM function in SAS for Windows 9.4 (SAS Institute,
Inc., Cary, NC) on a personal computer. The distribution of data was assessed via the
Shapiro-Wilk test utilizing PROC UNIVARIATE and determined to be approximately
normal. An alpha level of 0.05 was used to determine statistical significance. Significant
findings were explored by pairwise comparison using the LSMEANS function and
TUKEY adjustment.
For the oxime control studies, the distribution of data was assessed utilizing
PROC UNIVARIATE in SAS for Windows 9.4 (SAS Institute, Inc., Cary, NC) on a
personal computer. From assessment of the Shapiro-Wilk test and histograms, these data
were determined to be non-parametric due to the number of replicates (n = 4) for each
oxime tested. The PROC UNIVARIATE procedure was also used to carry out a
Wilcoxon signed rank test to determine if there was a significant difference in mean
absorbance between the oxime controls and tissue control. An alpha level of 0.05 was
used to determine statistical significance.
The determination of oxime EC25 was performed by graphing a scatterplot of
reactivation percentage as the dependent variable versus the independent variable oxime
35

concentration in Sigma Plot/SigmaStat 13 software on a personal computer. A hyperbola
was fit to the scatterplot in Sigma Plot regression wizard using the following equation:
y = 𝑦0 +

𝑎𝑥
𝑏+𝑥

(1.4)

The EC25 was calculated by assigning reactivation efficacy, the dependent
variable, as 25% and solving for the independent variable, concentration. The accuracy
of this method was checked via linear regression by logit transformation of the data and
plotting the log of the concentration versus the logit value of the reactivation percentage.
This check was performed in Microsoft excel on a personal computer.
Finally, for the in vitro reactivation studies, 3 pools of each age/sex group were
assessed for a total 12 pools. Distribution of the data was assessed utilizing PROC
UNIVARIATE in SAS for Windows 9.4 (SAS Institute, Inc., Cary, NC) and determined
to be non-parametric from assessment of the Shapiro-Wilk test and histograms. The nonparametric data from the in vitro reactivation studies was transformed via PROC RANK
and a two-way ANOVA performed with PROC GLM. Significant findings were
explored by pairwise comparison using the LSMEANS function and TUKEY adjustment.
Comparison of the two oxime combination dose groups (50 μM vs. 100 µM) was
assessed by a two-way ANOVA using a group by block factor method in PROC GLM.
An alpha level of 0.05 was used to determine statistical significance.
Results
To determine cholinesterase activity in rat brain homogenate at various age/sex
groups, a cholinesterase assay was performed utilizing whole rat brain from 3 different
naïve age groups (PND 1, PND 12, and PND 70) at the same concentration. Activity for
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the pooled rat brain homogenate at a concentration of 40 mg/ml (FC, 1 mg/mL) increased
with age as shown in Figure 2. Statistically significant differences (p < 0.05) were seen
between the PND 1 group versus all other groups and the PND 12 female group versus
the PND 70 male group. When rat brain homogenate for the PND 12 group was diluted
to 65 mg/ml (FC, 1.6 mg/mL), approximately equivalent cholinesterase activity to PND
70 was achieved and this concentration was utilized in the rest of the in vitro assays.
Before beginning any reactivation assays, the oximes and vehicles needed to be
tested to ensure that they did not significantly alter cholinesterase activity by themselves
in the absence of OP. Results from oxime control studies confirmed that cholinesterase
activity in the rat brain homogenate was not significantly (p > 0.05) altered from control
for any of the oximes or vehicles used in these experiments.
Dose-response curves were created from oxime-mediated reactivation of rat brain
homogenate inhibited by OP as shown in Figure 3 and 4. Reactivation percentages
produced by increasing concentrations of oxime were plotted and best-fit to a hyperbola
model. The models displayed a good fit to these data (R2 > 0.97) from which the EC25
for each oxime was calculated. The greatest in vitro reactivation efficacy was displayed
by 2-PAM against PXN and NIMP with EC25 values of 10.03 µM and 18.59 µM,
respectively. The novel oximes 15 and 55 were effective reactivators of PXN with EC25
values of 27.49 and 23.62 µM, respectively. All the oximes were not as effective against
NIMP and Ox 15 failed to achieve 25% maximal reactivation at the highest concentration
tested (FC, 1000 µM). High concentrations (FC, >250 µM) of several oximes exhibited
an inhibitory effect on reactivation and at concentrations higher than 0.1 M, most would
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not stay in solution utilizing DMSO:EtOH solvent. The calculated EC25 values for each
oxime are displayed in Table 2.
Reactivation studies were performed for each oxime against both OPs (PXN and
NIMP) utilizing rat brain homogenate pools for each of the age/sex groups (PND 12
female, PND 12 male, PND 70 female, PND 70 male) as previously described. Oximes
were tested singularly, and in combination with each other at an equimolar concentration
(FC, 100 µM) to the single oxime dose or at double this concentration (FC, 200 µM).
Data for these reactivation studies are contained in Tables 3 and 4 and represented
graphically in Figures 5 – 10 for easier interpretation.
Oximes used alone versus PXN-inhibited rat brain homogenate (Table 3) indicate
consistent reactivation percentages in all age/sex categories with 2-PAM garnering the
highest at 83% to 88% while the novel oximes yielded 46% to 52%, 26% to 29%, and
35% to 40% for oximes 15, 20, and 55, respectively. Statistically significant differences
(p < 0.05) were seen between some age/sex groups for oxime 15 and 55; however, there
does not appear to be a distinguishable pattern to the statistically different results
highlighted in Figure 5, a trend which also continues when observing the oxime
combinations used against PXN.
Statistically significant differences (p < 0.05) exist for the combinations of 2PAM and Oxime 20 as well as Oxime 15 and 20 against PXN in both the 100 µM and
200 µM concentrations as displayed in Figures 6 and 7; however, these differences are
very small. For example, for the combination of 2-PAM and Oxime 20 at 100 µM, the
statistically significant result is between the PND 70 male and PND 12 male groups with
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reactivation percentages of 71% versus 63%, respectively. The statistically significant
result for the other oxime combination at 100 µM, oxime 15 and 20, is even smaller at
44% versus 39% for the PND 70 male and PND 12 female groups, respectively. The
significant differences seen in single oxime therapy against PXN do not seem to carry
over in any way to the reactivation data for the oximes used in combination. The
relatively small amount of variation among the tested pools seems to be the main driver
of these statistically significant results with standard deviation reaching 1% or lower in
many cases.
When comparing oxime combinations against PXN at the two different therapy
concentrations, equimolar (Figure 6) versus double the single oxime dose (Figure 7),
these data indicate statistically significant (p < 0.05) increases in reactivation at the
higher concentration for all the combinations except for 2-PAM and oxime 15. None of
the oxime combinations at the equimolar dose met or exceeded a reactivation as high as
that achieved by a single oxime used alone. For example, for PND 70 males, 2-PAM
used alone (FC, 100 µM) achieved 88% reactivation while the highest reactivation for the
equimolar oxime combinations in that same age/sex group is 2-PAM + Ox55 at 77%.
The same is not true for the higher concentration at double the single dose (FC, 200 µM).
These data show that oxime 15 and 20 seem to have an inhibitory effect on reactivation
when combined with themselves or 2-PAM. Oxime 55, on the other hand, does not
display this same inhibitory trend on reactivation efficacy when combined with the other
oximes and achieves about the same cholinesterase activity when combined with oxime
15 or 2-PAM as compared to those oximes alone.
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When incubated with NIMP-inhibited rat brain homogenate, reactivation efficacy
for all the oximes (Table 4) was lower than that seen against PXN. For these in vitro
experiments, 2-PAM garnered the highest reactivation percentages across all age/sex
groups ranging from 65% to 72%, while both oxime 15 and 55 yielded comparatively
much lower reactivation activities. Comparison of the single oxime doses (FC, 100 µM)
yielded statistical significance (p < 0.05) with a noticeable pattern as displayed in Figure
8. For 2-PAM, oxime 15 and 20, reactivation in the adult (PND 70) brain homogenate
was statistically different from that in the juvenile (PND 12) tissue. While 2-PAM
seemed slightly more effective in PND 70 tissue, novel oximes 15 and 20 both displayed
significant increases in reactivation in PND 12 tissue versus PND 70.
When examining the oxime combinations against NIMP-inhibited rat brain
homogenate, this same pattern between age/sex groups remains consistent as
demonstrated in Figures 9 and 10. In almost all instances where oxime combinations
were used in equimolar concentration (FC, 100 µM) to the single oxime dose, there was
statistically significant differences (p < 0.05) between reactivation in PND 70 versus
PND 12 tissue. Sex-related statistically significant differences were detected for two
oxime combinations at this concentration; however, no consistent pattern in these data
suggest that these are not biologically significant variations. Oxime combinations at 200
µM used against NIMP again show a pattern of differences consistent with the other
oxime therapy concentrations. All combinations of novel oximes display increased
reactivation of PND 12 tissue versus PND 70, while combinations of 2-PAM at 200 µM
did not show any significant differences between age/sex groups. The latter may be due
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to an overall increased reactivation efficacy at higher concentrations of 2-PAM which
may be masking any potential differences.
Overall, regardless of age and sex, combinatorial oxime therapy at 100 µM does
not seem to confer any reactivation benefit when used against NIMP-inhibited tissue in
vitro. None of the oxime combinations at this concentration produced reactivation which
significantly increased as compared to the reactivation produced by the oximes when
used singularly; however, there are relevant results from the higher concentration (200
µM) oxime combinations. Oxime 15 in combination with 2-PAM at 200 µM
significantly reduced reactivation than that achieved by 2-PAM alone. Interestingly,
oxime 20 when combined with 2-PAM at 200 µM produced reactivation that was not
significantly different from 2-PAM alone, and only oxime 55 in combination with 2PAM at 200 µM significantly increased (p > 0.05) reactivation of NIMP-inhibited tissue
greater than that of 2-PAM alone.
Discussion
Much of these data presented in this chapter rely on accurate comparison of
cholinesterase activities between the age/sex groups of adult (PND 70) male and female
rat brain tissue and juvenile (PND 12) male and female rat brain tissue. We know from
previous reports that cholinesterase activity increases with age as rats mature (Coyle and
Yamamura, 1976). Data garnered from these experiments verify significant differences
in cholinesterase activity from PND 1, PND 12, and PND 70 rat brain tissue. While
reactivation assays report results as a percent of control, it was important to increase the
concentration of brain homogenate in PND 12 samples to be approximately equivalent to
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the cholinesterase activity of PND 70 rat brain tissue. This allows added oxime to react
with approximately the same amount of target enzyme in vitro, prevents shrinking the
analytical range of the assay, and mitigates a potential source of experimental bias which
could confound results.
In addition to ensuring an accurate comparison of cholinesterase activity, it was
also important to compare the effective concentration of the oximes themselves. Data
from previous experiments in this laboratory indicated that 2-PAM was a superior in vitro
reactivator of cholinesterase activity as compared to the novel oximes (Chambers et al.,
2013; Chambers et al., 2016b). The EC25 values calculated in this study confirm that 2PAM is more effective than novel oxime 15, 20, or 55 reactivating 25% of brain tissue
cholinesterase activity inhibited by PXN or NIMP at 10.03 µM and 18.59 µM,
respectively, whereas the EC25 values for all three novel oximes are higher. Despite the
effectiveness of 2-PAM in vitro, studies performed in vivo have demonstrated that our
novel oximes have provided enhanced survivability over 2-PAM in most cases against a
lethal dose of OP in rats. Both oximes 15 and 55 improved survivability against PXN
over 2-PAM, while oxime 15 and 20 improved survivability over 2-PAM against NIMP
(Chambers et al., 2016a; unpublished data). The EC25 values calculated in this study are
consistent with those previous findings showing that among the novel oximes, 15 and 55
had the best performance against PXN while oxime 20 was more effective against NIMP
as outlined in Table 2.
Previous studies in this laboratory investigating oxime reactivation of OPinhibited cholinesterase activity were conducted using adult male rats as the animal
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model (Chambers et al., 2013; Chambers et al. 2016b). In the present study, both male
and female rats of various ages were assessed. There was no statistical difference
demonstrated between males and females in either age category for any oxime-OP
combination which is consistent with the highly conserved nature of AChE described in
mammals (Massoulie et al., 1993).
Reactivation of PXN-inhibited AChE in rat brain with all the oximes indicated
consistent efficacy in each age/sex group. Although statistically significant differences
were observed, no clear pattern emerged with respect to age or sex. Furthermore, these
differences in reactivation within the groups do not seem to be physiologically relevant
and are likely due to the low amount of variability seen among the tested tissue pools.
These statistically significant differences seen in oxime reactivation of PXN-inhibited rat
brain AChE would likely diminish with a larger sample size.
Overall, the oximes were less effective reactivating NIMP-inhibited AChE, and 2PAM performed better than the novel oximes, again consistent with EC25 values
calculated. Interestingly, while 2-PAM showed slightly better efficacy in adults than
juveniles, the novel oximes 15 and 20 performed better in the latter groups. Statistical
significance (p < 0.05) was achieved with reactivation of NIMP-inhibited AChE and
these data indicate a pattern suggestive of an age-related difference present between
adults and juveniles but not between the sexes. A possible explanation for this agerelated difference may lie with proposed “non-classical”, morphogenic functions of
AChE beyond simple hydrolysis of acetylcholine. An association was found between
AChE and a glutamate receptor subtype, α-amino-3-hydroxy-5-methylisoxazole-443

propionic acid (AMPA), within the brain of developing rats to promote synaptogenesis
which diminishes with maturity. This is an example of an AChE-protein binding
interaction found primarily in juvenile rats which may sterically affect the reactivation of
AChE dependent upon which OP phosphorylates the enzyme and which oxime is used
for reactivation. Inhibitors targeting peripheral and catalytic binding sites on AChE
ameliorated the modulating effect of the enzyme on AMPA receptors (Soreq and
Seidman, 2001; Olivera et al., 2003). If the catalytic and peripheral binding sites are
involved with AMPA receptors promoting synaptogenesis in juvenile rats, this could
induce subtle deviations in or around the molecular structure of AChE in maturing rat
brain which may increase effectiveness of these novel oximes in juvenile tissue.
Comparison of the oxime combinations against either OP revealed that there was
no apparent benefit to reactivation at the lower dose (100 µM), which was equimolar to
the single oxime dose. In these combination studies, each oxime was added separately to
the reaction tube at 50 µM, both of which when added together yielded 100 µM total
oxime FC which was equimolar to the single dose as previously mentioned. It is
therefore, unclear if there was competitive inhibition between the oximes or if they were
acting as true chemical antagonists against each other; however, what is clear is that at
this concentration, there were no synergistic effects on reactivation.
With respect to the higher concentration oxime combinations, both oximes were
added separately to the reactivation assay at 100 µM, both of which when added together
yielded 200 µM FC. It is not surprising then that reactivation percentages at this
concentration significantly increased as compared to the lower concentration oxime
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combinations. One would also expect reactivation percentages to exceed those achieved
by the oximes used singly because there was twice the molar concentration of an
equivalent single concentration present; however, this was not observed for most of the
oximes. For this reason, the higher concentration oxime combinations may give better
insight as to which oximes work together and which do not. For example, addition of
oxime 15 to 2-PAM or oxime 20 significantly lowered reactivation when compared to 2PAM or oxime 20 used alone. Against either OP, oxime 55 did not appear to decrease
reactivation when combined with any oxime as compared to those oximes alone. Even
with the low reactivation of 8% to 11% garnered by oxime 55 alone against NIMP, when
combined with 2-PAM at the 200 µM concentration, oxime 55 seemed to have an
additive effect significantly increasing reactivation as compared to 2-PAM alone. These
data indicate that oxime 55 may be a good candidate for in vivo oxime combination
studies while oxime 15 may be inhibitory towards other oximes if used in combination.
Conclusion
The results obtained thus far indicate that the novel oximes will be equally
efficacious in males and females. There was no significant difference in reactivation by
any oxime in males versus females at either age tested. Performance of these oximes
depend upon the OP which is inhibiting AChE which was consistent with previous
research and confirmed in both the EC25 calculations as well as reactivation studies.
These data also indicate an age-related difference in reactivation of NIMP-inhibited
enzyme which could be confirmed with future in vivo studies if it were to be found that
these novel oximes improve survivability in juveniles. Additionally, these data seem to
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point to oxime 55 as a good candidate for combination therapy. The combination of 2PAM, as a potent peripheral reactivator, and oxime 55, as a reactivator which could cross
the blood-brain barrier to attenuate central nervous system inhibition has the potential to
boost survivability against an OP exposure event.
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Table 1

Assayed Oximes and Oxime Combinations

Oxime (s)
Final Concentration (μM)
Pralidoxime (2-PAM)
100
Novel Oxime 15 (Ox 15)
100
Novel Oxime 20 (Ox 20)
100
Novel Oxime 55 (Ox 55)
100
2-PAM + Ox 15
100
2-PAM + Ox 20
100
2-PAM + Ox 55
100
Ox 15 + Ox 20
100
Ox 15 + Ox 55
100
Ox 20 + Ox 55
100
2-PAM + Ox 15
200
2-PAM + Ox 20
200
2-PAM + Ox 55
200
Ox 15 + Ox 20
200
Ox 15 + Ox 55
200
Ox 20 + Ox 55
200
Single oximes and oxime combinations dissolved in 1:1 ethanol/ dimethyl sulfoxide
vehicle. Oximes used in combination added separately at 50 µM or 100 µM for the low
or high concentration, respectively to yield the final concentrations as calculated in 1 mL
total volume rat brain homogenate (40 mg/mL and 65 mg/mL for postnatal day (PND) 70
and PND 12, respectively) during the reaction step of the reactivation assay.
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Table 2

Oxime Effective Concentration for 25% Reactivation of OP-inhibited Rat
Brain

PXN
NIMP
Oxime
EC25 (µM)
R2
EC25 (µM)
R2
2-PAM
10.03
0.99
18.59
1.00
Ox 15
27.49
0.98
…
…
Ox 20
91.57
0.98
176.93
0.99
Ox 55
23.62
0.99
269.60
0.99
Multiple oxime concentrations were used to reactivate 1 mL adult male rat brain
homogenate (FC, 40 mg/mL) inhibited by either paraoxon (PXN) (FC, 100 nM) or 4nitrophenyl isopropyl methylphosphonate (NIMP) (FC, 56 nM). A dose-response
relationship curve was plotted and a hyperbola model was best-fit to these data yielding
the R2 values. Calculated EC25 values were determined from this model. Ox 15 could
not achieve 25% maximal reactivation against NIMP with concentrations up to 1 mM;
therefore, an EC25 value could not be calculated.
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Table 3

Reactivation Percentages of PXN-inhibited Rat Brain
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Oxime
FC (μM) PND 70 Male SD PND 70 Female SD PND 12 Male SD PND 12 Female SD
2-PAM
100
87.80
0.8
84.63
5.1
82.53
1.7
85.08
1.9
a
b,c
a,b,c
a
Ox 15
100
51.86
3.7
45.51
0.9
47.87
0.7
49.58
1.1
a
Ox 20
100
28.80
1.6
26.16
1.0
29.22
2.1
27.74
1.8
Ox 55
100
39.86 a
0.9
35.45 b
1.5
37.34 a
1.0
35.98 b
3.0
2-PAM + Ox 15
100
71.45
2.0
66.67
3.8
70.35
0.5
67.99
3.8
a
a,b
b
a,b
2-PAM + Ox 20
100
70.90
2.9
66.08
3.7
62.49
2.2
65.79
2.5
2-PAM + Ox 55
100
77.20
2.6
71.91
5.4
69.28
1.8
72.65
5.7
Ox 15 + Ox 20
100
44.07 a
0.8
41.35 a
1.4
40.34 b
1.8
39.36 b
1.9
Ox 15 + Ox 55
100
52.00
2.0
47.48
3.3
46.26
1.2
44.73
3.4
Ox 20 + Ox 55
100
36.35
2.6
32.18
0.3
33.41
2.6
32.28
3.0
2-PAM + Ox 15
200
74.88
0.8
72.12
2.7
70.85
6.7
69.37
3.3
2-PAM + Ox 20
200*
77.51 a
2.7
74.38 b
0.6
68.46 c
0.6
72.38 d
1.7
2-PAM + Ox 55
200*
84.83
2.6
80.36
3.9
79.64
2.4
80.28
2.6
a
a,b
b
a,b
Ox 15 + Ox 20
200*
46.51
0.5
43.29
0.4
41.08
2.4
40.48
5.8
Ox 15 + Ox 55
200*
54.16
1.7
51.70
4.0
49.17
3.4
47.15
3.8
Ox 20 + Ox 55
200*
41.17
0.6
40.94
1.3
37.97
3.1
38.11
3.2
Postnatal day (PND) 70 (40 mg/ml) and PND 12 (65 mg/ml) rat brain homogenate incubated with paraoxon (PXN) (100 nM).
Reactivation with 2-PAM, novel oximes 15, 20, 55 (100 μM) or in combination with each other at equimolar (100 μM) or
twice the equimolar concentration (200 μM) of the single oxime concentration. Reactivation results expressed as a percentage
(%) of control (standard deviation = SD). Differences in means between PND/sex groups compared via two-way ANOVA.
Mean reactivation percentages not indicated by the same letter are significantly different (p < 0.05). Differences in means
between oxime combination groups compared via two-way ANOVA (* = significantly different from 100 μM oxime
combination).

Table 4

Reactivation Percentages of NIMP-inhibited Rat Brain
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Oxime
FC (μM) PND 70 Male SD PND 70 Female SD PND 12 Male SD PND 12 Female SD
2-PAM
100
71.66 a
1.9
74.95 a
2.3
65.18 b
2.2
67.22 b
2.4
a
a
b
b
Ox 15
100
2.54
3.2
5.80
1.7
14.81
1.4
15.71
1.2
a
a
b
b
Ox 20
100
34.99
0.5
34.46
5.3
44.80
2.5
44.50
2.7
Ox 55
100
9.18
1.5
8.10
2.8
10.24
1.1
10.77
0.7
a
b
c
d
2PAM + Ox 15
100
4.26
1.4
11.60
3.7
19.49
2.1
21.49
1.6
a
a
b
b
2PAM + Ox 20
100
37.14
4.1
39.86
5.5
46.79
1.5
49.74
2.7
a
b
c
d
2PAM + Ox 55
100
50.81
1.9
57.29
3.2
48.51
1.7
52.74
2.3
Ox 15 + Ox 20
100
18.35 a
0.5
20.72 a
3.5
32.66 b
2.5
33.54 b
0.5
a
a
b
b
Ox 15 + Ox 55
100
0.46
2.9
1.95
2.2
12.35
0.8
11.88
1.4
a
a
b
b
Ox 20 + Ox 55
100
22.06
0.8
20.98
5.3
33.92
1.9
35.99
2.4
2PAM + Ox 15
200*
42.19
2.1
44.73
6.2
48.49
4.4
54.00
9.3
2PAM + Ox 20
200*
70.77
1.5
70.87
1.2
72.09
2.9
73.55
1.2
2PAM + Ox 55
200*
75.76
1.5
81.35
0.4
74.76
2.2
75.02
2.6
a
a
b
b
Ox 15 + Ox 20
200*
11.90
1.5
15.79
2.9
27.26
2.1
28.58
1.2
a
a
b
b
Ox 15 + Ox 55
200*
9.09
1.6
13.24
3.3
20.42
4.0
23.82
1.4
a
a
b
b
Ox 20 + Ox 55
200*
15.13
3.1
14.59
4.4
25.37
0.9
25.01
1.6
Postnatal day (PND) 70 (40 mg/ml) and PND 12 (65 mg/ml) rat brain homogenate incubated with 4-nitrophenyl isopropyl
methylphosphonate (NIMP) (56 nM). Reactivation with 2-PAM, novel oximes 15, 20, 55 (100 μM) or in combination with
each other at equimolar (100 μM) or twice the equimolar concentration (200 μM) of the single oxime dose. Reactivation
results expressed as a percentage (%) of control (standard deviation = SD). Differences in means between PND/sex groups
compared via two-way ANOVA. Mean reactivation percentages not indicated by the same letter are significantly different (p
< 0.05). Differences in means between oxime combination groups compared via two-way ANOVA (* = significantly different
from 100 μM oxime combination).
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Figure 1

Structure of Organophosphates and Novel Oximes (US patent 9,277,937)
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Figure 2

Rat Brain Cholinesterase Activity by PND/Sex Group

Rat brain homogenate (1 mg/mL) with vehicle control (1% EtOH v/v). Cholinesterase activity determined with 1 µM ATCh
substrate by modified Ellman assay. A two-way ANOVA assessed differences in mean absorbance between the multiple
postnatal day (PND)/sex groups. * = statistically different (p < 0.05) mean absorbance between PND groups
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Figure 3

Oxime Dose-response Curve of Reactivation in PXN-inhibited Rat Brain Homogenate

Adult male rat brain homogenate (40 mg/mL) inhibited by paraoxon (PXN) (100 nM) and reactivated with increasing
concentrations of 2-PAM, novel oximes 15, 20, or 55.
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Figure 4

Oxime Dose-response Curve of Reactivation in NIMP-inhibited Rat Brain Homogenate

Adult male rat brain homogenate (40 mg/mL) inhibited by 4-nitrophenyl isopropyl methylphosphonate (NIMP) (56 nM) and
reactivated with increasing concentrations of 2-PAM, novel oximes 15, 20, or 55. Oxime 20 produced maximum reactivation
at 500 µM, demonstrated reduced reactivation at 750 µM, and would not remain in solution at 1000 µM.
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Figure 5

Reactivation of PXN-inhibited Rat Brain

Postnatal day (PND) 70 (40 mg/ml) and PND 12 (65 mg/ml) rat brain homogenate incubated with paraoxon (PXN) (100 nM).
Reactivation with 2-PAM, novel oximes 15, 20, or 55 (100 μM). Reactivation expressed as a percentage (%) of control.
Differences in means between PND/sex groups for each oxime compared via two-way ANOVA. * = statistical significance (p
< 0.05)
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Figure 6

Reactivation of PXN-inhibited Rat Brain with Oxime Combinations

Postnatal day (PND) 70 (40 mg/ml) and PND 12 (65 mg/ml) rat brain homogenate incubated with paraoxon (PXN) (100 nM).
Reactivation with 2-PAM, novel oximes 15, 20, or 55 (50 μM) in combination with each other at an equimolar concentration
(100 μM) to the single oxime dose. Reactivation results expressed as a percentage (%) of control. Differences in means
between PND/sex groups for each oxime combination compared via two-way ANOVA. * = statistical significance (p < 0.05)

57
Figure 7

Reactivation of PXN-inhibited Rat Brain with Oxime Combinations at High Concentrations

Postnatal day (PND) 70 (40 mg/ml) and PND 12 (65 mg/ml) rat brain homogenate incubated with paraoxon (PXN) (100 nM).
Reactivation with 2-PAM, novel oximes 15, 20, or 55 (100 μM) in combination with each other at a concentration double (200
μM) the single oxime dose. Reactivation results expressed as a percentage (%) of control. Differences in means between
PND/sex groups for each oxime combination compared via two-way ANOVA. * = statistical significance (p < 0.05)
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Figure 8

Reactivation of NIMP-inhibited Rat Brain

Postnatal day (PND) 70 (40 mg/ml) and PND 12 (65 mg/ml) rat brain homogenate incubated with 4-nitrophenyl isopropyl
methylphosphonate (NIMP) (56 nM). Reactivation with 2-PAM, novel oximes 15, 20, or 55 (100 μM). Reactivation
expressed as a percentage (%) of control. Differences in means between PND/sex groups compared via two-way ANOVA.
* = statistical significance (p < 0.05) between PND groups
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Figure 9

Reactivation of NIMP-inhibited Rat Brain with Oxime Combinations

Postnatal day (PND) 70 (40 mg/ml) and PND 12 (65 mg/ml) rat brain homogenate incubated with 4-nitrophenyl isopropyl
methylphosphonate (NIMP) (56 nM). Reactivation with 2-PAM, novel oximes 15, 20, or 55 (50 μM) in combination with
each other at an equimolar concentration (100 μM) to the single oxime dose. Reactivation results expressed as a percentage
(%) of control. Differences in means between PND/sex groups for each oxime combination compared via two-way ANOVA.
* = statistical significance (p < 0.05) between PND groups; † = statistical significance (p < 0.05) between sex groups
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Figure 10

Reactivation of NIMP-inhibited Rat Brain with Oxime Combinations at High Concentrations

Postnatal day (PND) 70 (40 mg/ml) and PND 12 (65 mg/ml) rat brain homogenate incubated with 4-nitrophenyl isopropyl
methylphosphonate (NIMP) (56 nM). Reactivation with 2-PAM, novel oximes 15, 20, or 55 (100 μM) in combination with
each other at a concentration double (200 μM) the single oxime dose. Reactivation results expressed as a percentage (%) of
control. Differences in means between PND/sex groups for each oxime combination compared via two-way ANOVA.
* = statistical significance (p < 0.05) between PND groups
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CHAPTER III
ADULT FEMALE RAT SUSCEPTIBILITY TO A LETHAL DOSE OF
ORGANOPHOSPHATE WHEN TREATED WITH
NOVEL PYRIDINIUM OXIMES
Introduction
The focus of this chapter is the performance of the novel pyridinium oximes as
compared to pralidoxime (2-PAM) in adult female Sprague Dawley rats challenged with
a lethal dose of organophosphate (OP). As mentioned in the previous chapter, sex-related
differences in susceptibility to OP insecticides have been known for quite some time with
female rats typically regarded as more susceptible as determined by LD50 studies (Gaines
and Linder, 1986). Adult female rats have been shown to be more sensitive to the
parathion, the parent compound of paraoxon (PXN), than adult males. Presumably, this
is due to increased levels of testosterone in males which favorably oxidize parathion
more towards non-toxic metabolites as opposed to bioactivation to PXN. Male rats
treated with parathion were more resistant to acetylcholinesterase (AChE) inhibition as
measured in brain tissue (196 nmol/min·mg protein) versus their female counterparts (80
nmol/min·mg protein). However, gonadectomized female rats exposed to parathion and
treated with testosterone demonstrated higher resistance to AChE inhibition (193
nmol/min·mg protein) than gonadectomized male rats treated with estrogen (91
nmol/min·mg protein). There were no significant differences noticed when treating the
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animals directly with PXN indicating that the sex-related differences in susceptibility to
an OP is related to the metabolism of the parent compounds (Agarwal et al., 1982).
More recently, studies have been conducted to better characterize sex-related
differences in rats exposed to nerve agents which hypothesize that estrogenic sex
hormones are a determining factor in susceptibility (Pittel et al., 2018; Smith et al., 2015;
Wright et al., 2015). Although the exact mechanisms by which estrogens confer their
protective effects against OP compounds remains unclear, it was demonstrated that
female rats displayed significantly higher 24-hour sarin LD50 while in the proestrus phase
of their estrus cycle as compared to male rats. Because estradiol peaks during this phase,
it is thought that the higher concentration of estrogens better protected this group against
the nerve agent (Smith et al., 2015). For this reason, experimental design of research
involving OP exposure in females must take into account and control for the estrus cycle.
The estrus cycle of the female Sprague Dawley rat is considerably shorter than the
menstrual cycle in a human averaging about 4 – 5 days in length (Goldman et al., 2007).
There are four major stages of the estrus cycle: proestrus, estrus, metestrus, and diestrus.
Distinguishing between these stages can be easily performed via light microscopy (Cora
et al., 2015). By controlling for the stage of the estrus cycle, the experiments performed
in this research add another level of insurance that the true efficacy of oxime performance
will be measured. The known cyclical increases in sex hormone can be avoided which
could otherwise lead to an overestimation of protection conferred by an oxime in the
absence of such a control measure.
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Materials and Methods
Chemicals
The organophosphates used for the in vivo studies in this research, 4-nitrophenyl
isopropyl methylphosphonate (NIMP) and paraoxon (PXN), were synthesized by Dr.
Howard Chambers which structures were confirmed by nuclear magnetic resonance at the
Department of Chemistry at Mississippi State University. The novel oximes, which were
first synthesized by Dr. Howard Chambers, have been scaled up for production and have
been recently synthesized by SRI International (Menlo Park, CA). Both atropine and 2PAM were purchased from Sigma Chemical Co (St. Louis, MO). All other reagents used
in this research were purchased from the commercial vendors Sigma Chemical Co (St.
Louis, MO) or Thermo Fisher Scientific (Waltham, MA).
Animals
Adult female Sprague Dawley rats (Crl:CD(SD)BR) at postnatal day (PND) 70
were purchased from Envigo RMS, Inc. and housed in AAALAC accredited facilities at
Mississippi State University. All animals were held in temperature-controlled
environments with a 12-hour dark-light cycle, used Envigo 70-90 Sani Chips, laboratory
grade bedding and had free access to Envigo Rodent Diet, 18% protein laboratory rat
chow and tap water. Procedures performed for this research received prior approval by
the Mississippi State University Animal Care and Use Committee.
Estrus Cycle Check
The estrus cycle of each female rat was checked prior to advancing to the dosing
protocol. This check ensured that each animal was in the diestrus phase of their estrus
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cycle. This phase was chosen for two reasons. First, higher tolerance to OP lethality was
only seen during the proestrus phase which was presumed to be due to the surge of
estrogen associated with this stage of the estrus cycle (Smith et al., 2015). Second, the
diestrus phase has been estimated to be the longest in duration of all the stages lasting
about 48 – 72 hours which gives the largest window of opportunity to proceed to the
dosing protocol (Cora et al., 2015). An increased concentration of estrogen sex hormone
has the potential to cause overestimation of oxime efficacy. By performing the estrus
cycle check and confirming that each animal is in the diestrus stage, this allows for the
control of one potentially confounding variable.
In order to check the estrous cycle, a syringe was loaded with 100 µL of 0.9%
saline solution. The syringe was then gently placed into the vaginal orifice and the saline
was flushed into the vagina 2-3 times. Next, this lavage fluid was placed on a glass slide
and allowed to air dry with the help of a slide warmer. After completely dry, the slide
was stained in a three-step process utilizing Mercedes Medical QUIK-DIPTM
hematological stain. The slide was first dipped in a Coplin jar containing the first
reagent, 80% methyl alcohol, 5 times for 1-2 seconds per dip. The excess reagent was
drained off the slide with absorbent paper. Next, the slide was dipped in a Coplin jar
containing the second reagent, xanthene dye (1 g/L), 5 times for 1-2 seconds per dip. The
excess reagent was drained off the slide with absorbent paper. Finally, the slide was
dipped in a Coplin jar containing the third reagent, thiazine dye (1.1 g/L), 5 times for 1-2
seconds per dip. The excess reagent was drained off the slide with absorbent paper and
allowed to completely dry. The slides were then read by standard light microscopy using
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10x magnification to assess cell density and 40x magnification to identify cells using a
Fisher Scientific Micromaster® light microscope.
Dosing Protocol
The experimental paradigm used for the adult female rats closely followed the
same design used for adult males from previous studies (Chambers et al., 2016a). Initial
testing was performed to ensure the correct dose of PXN or NIMP to achieve LD99 results
after 24 hours with only the administration of 0.65 mg/kg atropine free base in saline.
That dose was determined to be 0.8 mg/kg and 0.6 mg/kg for PXN and NIMP,
respectively, which was the same as that used previously for the adult male rats. Each rat
was dosed with OP subcutaneously (s.c.), 2 minutes apart, except for one animal, which
was dosed with only vehicle (Multisol, a biocompatible solvent consisting of 48.5%
water, 40% propylene glycol, 10% ethanol, and 1.5% benzyl alcohol). Atropine and
oximes were administered intramuscularly (i.m.) 25-30 minutes after dosing with OP or
after onset of seizure-like signs (whichever comes first). One animal received only
atropine (0.65 mg/kg, i.m.) as an OP control, while the remaining animals additionally
received 1 of 4 oximes in Multisol (0.146 mmol/kg, i.m.): 2-PAM, oxime 15, oxime 20,
or oxime 55. Animals were closely monitored and assessed for signs of cholinergic
toxicity which followed a modified Racine scale for scoring seizures (Luttjohann et al.,
2009). These signs were scored as follows: (0) normal behavior; (1) oro-alimentary
movements (chewing); (2) anterior limb clonus and rearing; (3) loss of balance (falling)
and shaking; (4) tonic convulsions; (5) death. The observer was blinded as to which
oxime each animal received. Animals were observed closely for the first 8 hours
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following treatment to assess and score signs of toxicity, and scored one last time at the
24-hour mark to terminate the in vivo portion of the experiment. Animals which did not
exhibit seizure-like behavior after challenged with a lethal dose of OP were removed
from the study.
Tissue Collection and Preparation
Rats which survived the 24-hour survivability challenge were humanely
euthanized utilizing CO2 for anesthesia followed by decapitation. Animals which died
during the 8-hour surveillance period and those that survived 24 hours had tissues
harvested to include the brain, skeletal muscle, liver, and diaphragm which were snap
frozen in liquid nitrogen and stored at -80°C until they could be assayed. Whole blood
was collected from these animals and allowed to clot in a 1.5 mL plastic centrifuge tube
while kept on ice. The whole blood was then spun down using a centrifuge at 10,000
RCF at 4°C for 8 minutes. The serum was removed and kept frozen at -80°C until
assayed.
Whole rat brain were homogenized separately utilizing a motorized homogenizer
in 50 mM Tris HCl buffer (pH 7.4 at 25°C) to a stock solution of 40 mg/mL wet weight
equivalent. Skeletal muscle was cut into small pieces and then homogenized utilizing a
motorized homogenizer with blades in 50 mM Tris HCl buffer (pH 7.4 at 25°C) to a
stock solution of 100 mg/ml wet weight equivalent. This homogenate was then filtered to
remove any large particulate prior to assaying.
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Measurement of Cholinesterase Activity
As described in the previous chapter, cholinesterase activity in harvested tissues
was assayed utilizing a modified form of the Ellman discontinuous spectrophotometric
cholinesterase assay (Ellman et al., 1961). Rat brain or skeletal muscle homogenate was
added at volumes of 50 µL or 100 µL, respectively to 50 mM Tris HCl buffer (pH 7.4 at
25°C) for a total volume (TV) of 2 mL and final concentration (FC) of 1 or 5 mg/mL wet
weight equivalent, respectively. For each experimental unit, tissue was added to 5 tubes
for experimental replication with 2 tubes serving as tissue blanks and 3 tubes in which the
cholinesterase activity was measured. Both blanks received 20 µL of eserine sulfate (FC,
0.01 mM) which inhibits all cholinesterase activity in the tissue and served as a
measurement of background interference caused by any non-AChE hydrolysis of the
colorimetric substrate. All tubes were vortexed and incubated at physiologically relevant
temperature, 37°C, in a shaking water bath to ensure the assay remains well mixed for 15
minutes. Next, 20 µL of acetylthiocholine (ATCh) was added (FC, 1 mM) to all tubes
which serves as a substrate for the tissue AChE. This mixture was vortexed and
incubated again for another 15 min at 37°C in a shaking water bath. Finally the reaction
was terminated and color developed by the addition of 250 µL of a 4:1 mixture of 0.24 M
5,5’-dithio bis(2-nitrobenzoic acid) (DTNB) and 5% sodium dodecyl sulfate (SDS) to
each tube. Each sample was read at 412 nm utilizing a Thermo Scientific Biomate 3
spectrophotometer which produced absorbance values (A) directly proportional to the
amount of substrate hydrolyzed by AChE.
The enzymatic activity of AChE was targeted for assay in all harvested tissues,
however, butyrylcholinesterase (BChE) activity was also a target for assay in serum
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samples as well. Serum assays used 5 µL or 10 µL of undiluted serum for quantifying
AChE or BChE activity, respectively, which were added to 50 mM Tris HCl buffer (pH
7.4 at 25°C) for a TV of 1 mL. Similar to the protocol outlined above for other tissues,
five tubes were used for each experimental unit while all other reagents were added in
amounts scaled to a 1 mL TV assay. The two blanks received 10 µL of eserine sulfate
(FC, 0.01 mM) and all tubes were vortexed and incubated for 15 min at 37°C in a shaking
water bath. Next, 10 µL of ATCh or butyrylthiocholine (BTCh) were added to each tube
(FC, 1 mM) with BTCh acting as the preferred substrate for BChE to assess enzymatic
activity (Masson and Lockridge, 2010). This mixture was vortexed and incubated again
for another 15 min at 37°C in a shaking water bath. Finally, the reaction was terminated
and color developed by the addition of 125 µL of 0.24 M DTNB/5% SDS to each tube.
Each sample was read at 412 nm.
The method of Lowry et al. (1951) was used to quantify protein content of each
tissue sample using bovine serum albumin as the standard. Specific activities for all
tissues were calculated as nmoles min-1 mg P-1 using the equation outlined below:
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 = 𝐴 × 𝜀 ×

𝑇𝑉 (𝑚𝐿)
𝑇𝑐 (𝑚𝑔)

𝑇 𝑝 (𝑚𝑔)

1

× 𝐿𝑜𝑤𝑟𝑦 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 (𝜇𝑔) × 𝑡 (min) ×

1000 𝜇𝑔
1 𝑚𝑔

(3.1)

The absorbance (A) of the tissue homogenate is multiplied by the molar extinction
coefficient (𝜀) for SDS/DTNB which was determined to be 115.16 nmoles/mL·A by Dr.
Howard Chambers. This product is multiplied by the TV divided by the total amount of
tissue (Tc) in the cholinesterase assay. Next, the product is multiplied by the total amount
of tissue (Tp) used in the Lowry protein assay divided by the determined protein content.
Finally, the product is multiplied by the reciprocal of time used for incubation in the
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cholinesterase assay (t = 15 min) and by a conversion factor to arrive at the desired units
for specific activity.
Statistical Methods
The effect of oxime treatment on survival and odds ratios were calculated using 2PAM as the referent with PROC LOGISTIC in SAS for Windows 9.4 (SAS Institute,
Inc., Cary, NC.). Statistical significance was determined using an alpha level of 0.1
rather than 0.05 in order to reduce the number of animals needed for the dosing protocol
while still allowing for statistical power. Differences in mean time of cessation of
seizure-like behavior were determined using PROC LIFETEST in SAS for Windows 9.4.
Data were censored if the animal died before the end of the 8-hour observational period
or if seizure-like behavior continued past this window. The log-rank test statistic was
used to assess significance and Dunnett’s adjustment used for multiple comparisons of
the novel oximes against 2-PAM. Differences in mean cholinesterase activity from
harvested tissues between oxime treatments were determined by ANOVA using PROC
GLM in SAS for Windows 9.4 with TUKEY adjustment, and an alpha level of 0.05 was
used to determine statistical significance.
Results
Determination of the rat estrus cycle was performed prior to initiation of the
dosing protocol. Each phase of the estrus cycle was identified by examining the vaginal
cytology of each rat as outlined in Cora et al. (2015). The proestrus phase was
characterized by small nucleated epithelial cells of low to moderate density found
individually or in clumps (Figure 11). Estrus was defined by the presence of
71

predominantly anucleated keratinized epithelial cells (Figure 12). Metestrus was rarely
seen as this phase is very short lasting about 6 – 8 hours. A combination of anucleated
keratinized epithelial cells and neutrophils are seen in this phase with the number of
neutrophils often outnumbering the epithelial cells 10:1. Finally, the last stage of interest,
diestrus, was characterized by a substantial decrease in the number of epithelial cells seen
with varying numbers of neutrophils present. This phase has low to moderate cell density
and although the number of neutrophils can vary, they are always present in diestrus
(Figure 13).
After the female rats were determined to be in the diestrus phase of the estrus
cycle, the experiment proceeded to the dosing protocol ensuring that enough animals
were available to represent each oxime in every experimental group of rats. All animals
were administered with a LD99 dosage of either PXN or NIMP except those serving as
controls receiving only Multisol and atropine. Of those animals dosed with OP receiving
atropine only as therapy, none survived when challenged with NIMP while only one
survived against PXN. Most died shortly after being challenged with OP during the 8hour observational period with the average time to death being about 1 hour for both
PXN and NIMP.
Animals treated with novel oximes showed improvement over 2-PAM against
both OP compounds in 24-hr survivability. The percentage of improvement for the novel
oximes as compared to 2-PAM is shown in Figure 14. Novel oximes 15 and 55
demonstrated the best performance against PXN increasing the odds of survival by 6.5
and 3.1 times that of survivability with 2-PAM, respectively. Novel oxime 20 performed
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the best against NIMP significantly increasing (p < 0.1) survivability with an odds ratio
of 3.2 as compared to 2-PAM. Only oxime 55 did not increase 24-hour survivability as
compared to 2-PAM when the animals were challenged with a lethal dose of NIMP.
Survival data for all treated groups are summarized in Table 5.
Time to seizure cessation were evaluated for all four oximes against both PXN
and NIMP for rats surviving the 8-hour observational period (Table 6). Novel oxime 55
performed the best against PXN significantly reducing (p < 0.05) seizure-like behavior by
2 hours on average as compared to 2-PAM. A Kaplan-Meier plot demonstrates the
performance of all the oximes against PXN in reducing seizure-like behavior in Figure
15. Novel oxime 20 performed the best against NIMP significantly reducing (p < 0.05)
seizure-like behavior by 1.8 hours on average as compared to 2-PAM. A Kaplan-Meier
plot demonstrates the performance of all the oximes against NIMP in reducing seizurelike behavior in Figure 16. Overall, the novel oximes produced an average reduction in
the duration of seizure-like behavior of about 1-1.5 hours by comparison with 2-PAM.
The cholinesterase activity of brain, skeletal muscle, and serum was assessed for
those adult female rats surviving 24 hours (Tables 7-9). In most of the assayed tissues,
there was no difference in mean activity among the oxime treatment groups. There was
one statistical difference (p < 0.05), mean serum activity of AChE and BChE was higher
in the oxime 15 treated group than the other oxime groups when rats were challenged
with NIMP. Correspondingly, mean inhibition percentages were lower while recovery of
enzymatic activity was higher for NIMP-dosed animals treated with oxime 15 as
compared to the other oximes. These differences in the serum of NIMP-dosed animals
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were not seen in the PXN-treated group as all the oximes seem to better protect against
cholinesterase inhibition by PXN.
Discussion
In order to further the development of these novel oximes as a potential
improvement to current organophosphate treatment, new information was needed to
ensure that they have similar effects between males and females. This study was
designed to mimic previous studies done in this laboratory which tested the efficacy of
the novel oximes in adult male rats (Chambers et al., 2016a). Data from additional
studies on adult male rats which have not been published as of the writing of this
dissertation were also consulted for comparison with the data garnered in this research
involving adult female rats.
Compared to adult male rats, their female counterparts in this study displayed
very similar 24-hour survivability improvements when treated with the novel oximes as
compared to 2-PAM. These similarities were evident even with the fact that the same
lethal doses of PXN (0.8 mg/kg, s.c.) and NIMP (0.6 mg/kg, s.c.) were used on both
sexes. The percentage of adult male rats dosed with PXN surviving 24 hours and treated
with novel oximes 15, 20, and 55 was 85%, 30%, and 70%, respectively (unpublished
data). In this study, the percentage of adult female rats dosed with PXN surviving 24
hours and treated with novel oximes 15, 20, and 55 was 94%, 78%, and 89%,
respectively. Looking at oxime efficacy against a lethal dosage of the sarin surrogate,
NIMP, the percentage of adult male rats surviving 24 hours and treated with novel
oximes 15, 20, and 55 was 60%, 55%, and 30%, respectively (Chambers et al., 2016a;
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unpublished data). In this study, the percentage of adult female rats dosed with NIMP
surviving 24 hours and treated with novel oximes 15, 20, and 55 was 56%, 67%, and
28%, respectively.
From the comparison above, it has been demonstrated that these novel oximes all
improve survivability as compared to 2-PAM except for oxime 55 against lethal doses of
NIMP. All oximes, including 2-PAM, seemed to perform better in adult female rats
dosed with PXN in this study compared to the male rats. Since these animals were dosed
with PXN, and not the parent compound parathion, a mechanism based on OP
metabolism seems an unlikely explanation for this difference. Indeed, as mentioned
previously, Agarwal et al. (1982) demonstrated there was no difference seen in PXN
toxicity between male and female rats.
During the initial 8-hour observation period of the dosing protocol, the female rats
were closely monitored to record the time of cessation of seizure-like behavior. Novel
oximes decreased the time to cessation of seizure-like behavior as compared to 2-PAM
with oxime 55 and 20 significantly reducing (p < 0.05) seizure time against PXN and
NIMP, respectively. This reduction in seizure-like behavior aligned with the increased
survival percentages seen with the novel oximes, although this seizure-like behavior
cessation was not as pronounced as that seen earlier in male rats. The novel oximes in
male rats reduced seizure-like behavior on average 2-3 hours sooner in comparison with
2-PAM which offered little to no protection (unpublished data). For female rats, again 2PAM performed better against PXN in this study such that the novel oximes produced an
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average reduction in the duration of seizure-like behavior of about 1-1.5 hours by
comparison.
While it is difficult to determine if these differences seen between the sexes in
two separate studies are significant, what is clear is that oxime therapy is more successful
against PXN than NIMP. This is most likely due to the fact that experimentally
determined inhibition kinetics show that NIMP is indeed more potent than PXN (Coban
et al., 2016). Additionally, aging probably occurs much faster with NIMP-inhibited
AChE than it does with PXN. Aging halftimes for sarin have been experimentally
determined to be about 3 hours while aging of diethyl-phosphorylated AChE, as a result
of PXN inhibition, occurs in about 32 hours (Worek et al., 2004). It appears from these
data that adult female rats dosed with PXN seem to respond slightly better to therapy than
the adult males demonstrating slightly improved survivability and cessation of seizurelike behavior with all oximes, including 2-PAM. This observation may be indicative of
the ability of estrogenic sex hormones to bolster physiological defenses against OPs, such
as the blood-brain barrier, as proposed in other reports which indicate that females are
better protected against experimentally-induced brain damage than males (Pittel et al.,
2018).
Analysis of harvested tissues from 24-hour survivors challenged with a lethal OP
dose show that there was largely no difference in mean inhibition or reactivation of
cholinesterase activity between the oxime treatment groups with the one exception being
the performance of oxime 15 in NIMP-inhibited serum. In the absence of any additional
trends in cholinesterase activity from the other tissues, it is difficult to ascertain if this
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statistically significant result bears any physiological significance. The lack of any other
appreciable differences are most likely due to the experimental design of this research
which uses high concentrations of OP and relatively quick administration of oxime
(usually within 25-30 min of dosing with OP). These high concentrations of circulating
OP would be available to re-inhibit cholinesterase enzyme reactivated by oxime.
Other studies have been performed which were designed to prevent this
phenomenon of re-inhibition by using a smaller, sub-lethal dose of OP and waiting about
1 hour before oxime administration when maximal enzyme inhibition presumably should
have occurred. This allows for the circulating concentration of OP to diminish before
oxime administration mitigating the risk of re-inhibition (Chambers et al., 2013). Using
this paradigm, oxime 20 has demonstrated about 25% reactivation of NIMP-inhibited rat
brain AChE with little to no reactivation by 2-PAM which would be more consistent with
the 24-hour survivability data seen in this research (Chambers et al., 2016b).
Conclusion
The data presented here demonstrate improved survivability with our novel
oximes as compared to 2-PAM against both OP compounds. All the novel oximes tested
against PXN increased 24-hour survivability as compared to 2-PAM at the same molar
equivalent. Novel oxime 20 performed the best against the sarin surrogate, NIMP,
significantly (p < 0.1) improving 24-hour survivability 3.2 times greater than 2-PAM.
While the 24-hour survival percentages in these data with female rats were not
statistically significant at p < 0.05, the results are trending towards similar patterns of
improvements over 2-PAM as those seen in male rats from previous studies (Chambers et
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al., 2016a; unpublished data). Reduced seizure-like behavior was seen in animals treated
with novel oximes as compared to 2-PAM. Novel oximes 55 and 20 significantly
reduced (p < 0.05) the time of cessation of seizure-like behavior against PXN and NIMP,
respectively. These data provide additional support to the concept that our novel oximes
can enter the brain.
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Table 5

24-Hour Survival of Treated Rats with Lethal Dosages of Organophosphate
PXN

NIMP
Odds
Ratio

Odds
Ratio

Oxime
Surv./Trted. %Surv.
Surv./Trted. %Surv.
None
0/18
0
1/18
6
2-PAM
7/18
39
13/18
72
Oxime 15
10/18
56
2.0
17/18
94
6.5
Oxime 20
12/18
67
3.2*
14/18
78
1.4
Oxime 55
5/18
28
0.6
16/18
89
3.1
Percent survival after 24 hours of adult (PND 70) female rats treated with paraoxon
(PXN) (0.8 mg/kg s.c.) or 4-nitrophenyl isopropyl methylphosphonate (NIMP) (0.6
mg/kg s.c.) followed at 30 min by atropine (0.65 mg/kg i.m.) and oxime (0.146 mmol/kg
i.m.) or Multisol vehicle control. Odds ratios were calculated for survival against 2PAM. * = statistical significance (p < 0.1) vs 2-PAM
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Table 6

Cessation of Seizure-like Behavior in Rats Surviving 8 Hours
PXN

NIMP

Oxime
n
Time
p Value
n
Time
p Value
2-PAM
9
15
7.3 ± 1.2
8.0 ± 0
Oxime 15
13
0.858
17
5.9 ± 2.0
0.097
7.6 ± 0.9
Oxime 20
14
0.001
15
6.3 ± 1.6
0.115
6.2 ± 2.2
Oxime 55
8
0.343
17
5.2 ± 1.7
0.001
6.9 ± 1.7
Results expressed as average time (hours) until the cessation of seizure-like behavior in
female rats treated with paraoxon (PXN) (0.8 mg/kg s.c.) or 4-nitrophenyl isopropyl
methylphosphonate (NIMP) (0.6 mg/kg s.c.) followed at 30 min by atropine (0.65 mg/kg
i.m.) and oxime (0.146 mmol/kg i.m.). Statistical significance (p < 0.05) determined vs
2-PAM.
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Table 7

Tissue Specific Activity from Adult Female Rats Surviving 24 Hours
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PXN
NIMP
Serum
Serum
Oxime
n
Brain
AChE
BChE
SKM
n
Brain
AChE
BChE
SKM
Control
10 97.9 ± 9.4 34.6 ± 7.1 12.8 ± 2.5 10.3 ± 2.3 10 95.0 ± 12.8 30.9 ± 5.6
11.6 ± 1.9 12.7 ± 1.9
2-PAM
13 37.0 ± 7.8 26.4 ± 5.4
9.9 ± 2.5 7.6 ± 2.3 7 17.7 ± 1.5
13.6 ± 4.4
5.3 ± 2.1
4.1 ± 0.7
Oxime 15 17 36.3 ± 3.8 27.0 ± 5.7 10.0 ± 2.4 7.2 ± 1.7 10 14.8 ± 3.5
20.3 ± 5.5* 8.5 ± 2.7* 5.3 ± 1.6
Oxime 20 14 37.2 ± 2.9 26.9 ± 6.4 10.2 ± 2.9 6.3 ± 1.3 12 19.0 ± 12.3 15.6 ± 4.0
6.0 ± 1.9
5.2 ± 1.4
Oxime 55 16 37.8 ± 5.8 28.0 ± 9.1 11.0 ± 4.8 11.0 ± 4.8 5 14.3 ± 1.3
16.7 ± 2.1
7.0 ± 1.1
4.3 ± 1.7
-1
-1
Specific activities expressed as nmoles min mg P , means ± standard deviation in rats surviving 24 hours after treatment
with paraoxon (PXN) (0.8 mg/kg s.c.) or 4-nitrophenyl isopropyl methylphosphonate (NIMP) (0.6 mg/kg s.c.) followed at 30
min by atropine (0.65 mg/kg i.m.) and oxime (0.146 mmol/kg i.m.). The control animals were not treated with OP, only with
Multisol vehicle and atropine (0.65 mg/kg i.m.), and are referenced here for comparison against OP treated animals.
* = statistical significance (p < 0.05) vs 2-PAM
AChE = acetylcholinesterase; BChE = butyrylcholinesterase; SKM = skeletal muscle

Table 8

Tissue Inhibition from Adult Female Rats Surviving 24 Hours
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PXN
NIMP
Serum
Serum
Oxime
n
Brain
AChE
BChE
SKM
n
Brain
AChE
BChE
SKM
2-PAM
13 62 ± 8.0 24 ± 15.2 25 ± 16.4 27 ± 20.4 7
81 ± 1.8
60 ± 11.4
59 ± 15.1
68 ± 5.7
Oxime 15 17 63 ± 3.9 22 ± 16.0 24 ± 18.8 31 ± 15.1 10
84 ± 3.6
36 ± 17.9*
29 ± 23.3* 60 ± 12.5
Oxime 20 14 62 ± 3.0 23 ± 16.1 23 ± 18.8 38 ± 12.5 12
80 ± 12.9
50 ± 13.0
49 ± 16.8
59 ± 11.3
Oxime 55 16 61 ± 5.9 23 ± 17.9 23 ± 20.8 36 ± 18.7 5
85 ± 1.4
46 ± 8.9
40 ± 8.9
66 ± 13.2
Inhibition expressed as a percentage (%), means ± standard deviation in rats surviving 24 hours after treatment with paraoxon
(PXN) (0.8 mg/kg s.c.) or 4-nitrophenyl isopropyl methylphosphonate (NIMP) (0.6 mg/kg s.c.) followed at 30 min by atropine
(0.65 mg/kg i.m.) and oxime (0.146 mmol/kg i.m.).
* = statistical significance (p < 0.05) vs 2-PAM
AChE = acetylcholinesterase; BChE = butyrylcholinesterase; SKM = skeletal muscle

Table 9

Tissue Recovery from Adult Female Rats Surviving 24 Hours
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PXN
NIMP
Serum
Serum
Oxime
n
Brain
AChE
BChE
SKM
n
Brain
AChE
BChE
SKM
2-PAM
13 36 ± 8.3 69 ± 19.9 64 ± 23.9 68 ± 23.7 7
15 ± 1.6
24 ± 19.5
21 ± 22.5
7 ± 6.6
Oxime 15 17 35 ± 4.0 71 ± 20.9 65 ± 22.9 64 ± 17.6 10
12 ± 3.9
53 ± 24.3*
58 ± 33.8* 19 ± 16.8
Oxime 20 14 36 ± 3.1 69 ± 21.1 67 ± 27.4 56 ± 14.5 12
17 ± 13.7
32 ± 17.7
27 ± 24.2
18 ± 15.7
Oxime 55 16 36 ± 6.1 70 ± 23.4 67 ± 30.4 58 ± 21.7 5
12 ± 1.4
37 ± 9.4
40 ± 13.8
11 ± 15.6
Recovery expressed as a percentage (%), means ± standard deviation in rats surviving 24 hours after treatment with paraoxon
(PXN) (0.8 mg/kg s.c.) or 4-nitrophenyl isopropyl methylphosphonate (NIMP) (0.6 mg/kg s.c.) followed at 30 min by atropine
(0.65 mg/kg i.m.) and oxime (0.146 mmol/kg i.m.).
* = statistical significance (p < 0.05) vs 2-PAM
AChE = acetylcholinesterase; BChE = butyrylcholinesterase; SKM = skeletal muscle

Figure 11

Vaginal Cytology of Proestrus Phase at 40x Magnification in an Adult
Female Sprague Dawley Rat.
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Figure 12

Vaginal Cytology of Estrus Phase at 40x Magnification in an Adult Female
Sprague Dawley Rat.
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Figure 13

Vaginal Cytology of Diestrus Phase at 40x Magnification in an Adult
Female Sprague Dawley Rat. A neutrophil is indicated with an arrow.
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Figure 14

24-Hour Survival Improvement in Treated Rats Compared to 2-PAM.

Percent improvement in survival (24-hour) of treated rats with lethal dosages of paraoxon
(PXN) (0.8 mg/kg, s.c.) and 4-nitrophenyl isopropyl methylphosphonate (NIMP) (0.6
mg/kg, s.c.), atropine (0.65 mg/kg, i.m.), and novel oximes (0.146 mmol/kg, i.m.)
compared to 2-PAM.
* = statistical significance (p < 0.1) vs 2-PAM
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Figure 15

Novel Oxime Cessation of Seizure-like Behavior Against PXN.

Kaplan-Meier analysis of time to cessation of seizure-like behavior during the first 8
hours following paraoxon (PXN) administration (0.8 mg/kg, s.c.) in rats treated with
atropine (0.65 mg/kg, i.m.) and oximes (0.146 mmol/kg, i.m.). Statistical analysis results
of novel oximes compared to 2-PAM alone: Oxime 15, p = 0.097; Oxime 20, p = 0.115;
Oxime 55, p = 0.001.
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Figure 16

Novel Oxime Cessation of Seizure-like Behavior Against NIMP.

Kaplan-Meier analysis of time to cessation of seizure-like behavior during the first 8
hours following 4-nitrophenyl isopropyl methylphosphonate (NIMP) administration (0.6
mg/kg, s.c.) in rats treated with atropine (0.65 mg/kg, i.m.) and oximes (0.146 mmol/kg,
i.m.). Statistical analysis results of novel oximes compared to 2-PAM alone: Oxime 15,
p = 0.858; Oxime 20, p = 0.001; Oxime 55, p = 0.343.
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CHAPTER IV
CONCLUSION
The usage of organophosphate (OP) compounds continues to be a threat to human
health, particularly when employed as chemical weapons. Recently, on February 3,
2017, two women with ties to North Korea used their bare hands to apply nerve agent to
the face of Kim Jong-nam, the older brother of North Korean Dictator, Kim Jong-un.
The attack ended with the death of their target as well as one of the women becoming
severely ill. It is thought that they used a derivative of the nerve agent VX, VX2, which
consists of two compounds that are harmless by themselves, but become toxic when
mixed together (Paddock et al., 2017). On March 4, 2018, an obscure OP nerve agent,
Novichok, was used in an assassination attempt against a former Russian spy. This nerve
agent was presumably developed by the Russians and is estimated to be 5 times more
potent than VX or sarin (Sang, 2018). Despite the continued usage of OP nerve agents,
and their apparent novel formulations, drug therapy countermeasures such as treatment
using oximes has not changed since the early 1960s. Current OP therapy in the United
States still relies on the first oxime utilized in a clinical setting, pralidoxime (2-PAM), as
the reactivator of choice which was developed in 1955 (Childs et al., 1955; Worek et al.,
2016).
The primary goal of this research, and other previously mentioned research from
this laboratory, is providing evidence that our novel oximes are better reactivators which
demonstrate improved survivability due to an improved ability to better penetrate the
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blood-brain barrier as compared to 2-PAM. Much of the initial studies conducted in this
laboratory, as well as some unpublished data, were performed using adult male rats as the
animal model (Chambers et al., 2013; Chambers et al., 2016a; Chambers et al., 2016b).
Therefore, the focus of these experiments was to demonstrate that our novel oximes
perform with similar efficacy in adult female rats and, to a lesser extent, juvenile rats of
both sexes.
In the first part of this study, a number of in vitro experiments were performed to
assess cholinesterase activity of rat brain tissue, and to compare oxime efficacy and
oxime-mediated reactivation of OP-inhibited AChE in different age and sex groups. Data
from these experiments indicate that all of the novel oximes reactivate OP-inhibited
acetylcholinesterase (AChE) with equal efficacy in male and female rats of both age
groups tested, post-natal day (PND) 70 and 12. There was one statistically significant
difference (p < 0.05) detected when comparing the age groups. Oximes 15 and 20
demonstrated about a 10% improvement in reactivation of PND 12 brain AChE inhibited
by 4-nitrophenyl isopropyl methylphosphonate (NIMP) as compared to the PND 70 age
group. While the mechanism for this improvement in juvenile tissue is unknown, future
in vivo experiments could confirm this age-dependent increase in reactivation efficacy if
juvenile rats dosed with NIMP displayed improved survivability in comparison to their
adult counterparts.
Oxime efficacy was compared via calculation of the effective concentration at
which 25% reactivation (EC25) was achieved. For both OPs, paraoxon (PXN) and NIMP,
2-PAM required the lowest concentration to achieve an EC25. This observation was
confirmed in the other in vitro studies where 2-PAM consistently performed the best
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against both OPs with the highest reactivation percentages of all the oximes studied. This
performance, however, does not translate into improved survivability during in vivo
studies where the novel oximes outperform 2-PAM at the same molar equivalent dosage
in this research with adult female rats as well as past reports with adult male rats
(Chambers et al., 2013; Chambers et al., 2016a; Chambers et al., 2016b). This is the
main difference between 2-PAM and the novel oximes which lends evidence towards the
theory that these new oximes are better suited to cross the blood-brain barrier to
reactivate inhibited brain AChE. Even though 2-PAM consistently outperforms the novel
oximes during in vitro reactivation studies, small improvements in blood-brain
permeability can have large impacts on therapy against OP toxicity as even partial
reactivation has been shown to significantly reduce the amount of atropine needed to treat
a patient (Thiermann et al., 2011).
The second part of this study focused on demonstrating in vivo efficacy of our
novel oximes as compared to 2-PAM in adult female rats. The novel oximes
demonstrated improved survivability approximately equivalent to that seen in adult male
rats. Survivability data from the adult female rats in this experiment show that oxime 15
and 55 perform the best against PXN, while oxime 20 had the best odds ratio against
NIMP. The EC25 values determined in the first part of this study predicted that Oximes
15 and 55 would be more effective against PXN than Oxime 20 while the latter would be
the most effective of the novel oximes against NIMP. These in vitro predictions matched
with the improvements seen in the in vivo survivability experiments.
More evidence from this research towards the idea that these novel oximes better
penetrate the blood-brain barrier as compared to 2-PAM is the time to cessation of
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seizure-like behavior demonstrated in the in vivo study among the treatment groups. All
of the novel oximes reduced the time to cessation of seizure-like behavior as compared to
2-PAM against both OPs. Significant reductions (p < 0.05) in seizure-like behavior were
seen for the oxime 20 and 55 treatment groups when the rats were challenged with NIMP
and PXN, respectively.
This research utilized two OP compounds, PXN which is the active metabolite of
the insecticide parathion, and the other, NIMP, a surrogate for the nerve agent, sarin.
This was done to demonstrate broad spectrum effectiveness, and improvement of our
novel oximes over 2-PAM. These data indicate improved survivability and reduced
duration of seizure-like behavior against both compounds. While more studies will be
needed to further development and to garner evidence of improved efficacy against
traditional oxime therapy, this research demonstrates that these novel oximes show great
promise as the first improvements to antidotes against acute OP toxicity in 60 years.
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DISCLAIMER
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The views expressed in this dissertation are those of the author and do not reflect
the official policy or position of the United States Air Force, Department of Defense, or
the U.S. Government.
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